

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 088 900 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
04.04.2001 Bulletin 2001/14

(21) Application number: **99118120.7**

(22) Date of filing: **10.09.1999**

(51) Int Cl.⁷: **C12Q 1/68, C12P 19/34,
C12N 9/02, C07K 16/18,
C12N 15/53, A61K 38/17,
A61P 35/00, A01K 67/027**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(71) Applicant: **Epidauros Biotechnologie AG
82347 Bernried (DE)**

(72) Inventor: **The designation of the inventor has not
yet been filed**

(74) Representative: **VOSSIUS & PARTNER
Siebertstrasse 4
81675 München (DE)**

(54) **Polymorphisms in the human CYP3A4, CYP3A7 and hPXR genes and their use in diagnostic and therapeutic applications**

(57) Described are general means and methods of diagnosing and treating the phenotypic spectrum as well as the overlapping clinical characteristics with several forms of inherited abnormal expression and/or function of the CYP3A4, CYP3A7 and hPXR genes. In particular, polynucleotides of molecular variant CYP3A4, CYP3A7 and hPXR genes which, for example, are associated with insufficient metabolism and/or sensitivity of drugs, and vectors comprising such polynucleotides are provided. Furthermore, host cells comprising such polynucleotides or vectors and their use for the production of variant CYP3A4, CYP3A7 and hPXR proteins are described. In addition, variant CYP3A4, CYP3A7 and hPXR proteins and antibodies specifically recognizing

such proteins as well as transgenic non-human animals comprising the above-described polynucleotide or vectors are provided. Described are also methods for identifying and obtaining inhibitors for therapy of disorders related to the malfunction of the CYP3A4, CYP3A7 and hPXR genes as well as methods of diagnosing the status of such disorders. Pharmaceutical and diagnostic compositions comprising the above-described polynucleotides, vectors, proteins, antibodies and inhibitors by the above-described method are provided. Said compositions are particularly useful for diagnosing and treating various diseases with drugs that are substrates, inhibitors or modulators of the CYP3A4, CYP3A7 or hPXR gene product.

EP 1 088 900 A1

Description**Field of the invention**

[0001] The present invention relates generally to means and methods of diagnosing and treating the phenotypic spectrum as well as the overlapping clinical characteristics with several forms of inherited abnormal expression and/or function of the cytochrome P-450 (CYP)3A4 and CYP3A7 and the human pregnane X receptor (hPXR) genes. In particular, the present invention relates to polynucleotides of molecular variant CYP3A4, CYP3A7 and hPXR genes which, for example, are associated with abnormal drug response or individual predisposition to several common cancers caused by environmental carcinogens, and to vectors comprising such polynucleotides. Furthermore, the present invention relates to host cells comprising such polynucleotides or vectors and their use for the production of variant CYP3A4, CYP3A7 and hPXR proteins. In addition, the present invention relates to variant CYP3A4, CYP3A7 and hPXR proteins and antibodies specifically recognizing such proteins. The present invention also concerns transgenic non-human animals comprising the above-described polynucleotide or vectors. Moreover, the present invention relates to methods for identifying and obtaining drug candidates and inhibitors for therapy of disorders related to the malfunction of the CYP3A4, CYP3A7 and hPXR genes as well as to methods of diagnosing the status of such disorders. The present invention furthermore provides pharmaceutical and diagnostic compositions comprising the above-described polynucleotides, vectors, proteins, antibodies, and drugs and inhibitors obtainable by the above-described method. Said compositions are particularly useful for diagnosing and treating various diseases with drugs that are substrates, inhibitors or modulators of the CYP3A4, CYP3A7 and hPXR genes or their product. Several documents are cited throughout the text of this specification. Each of the documents cited herein (including any manufacturer's specifications, instructions, etc.) are hereby incorporated herein by reference; however, there is no admission that any document cited is indeed prior art as to the present invention.

Background of the invention

[0002] Members of the cytochrome P-450 (CYP) family of hemoproteins metabolise a wide variety of endogenous substrates such as steroid hormones, and of xenobiotics including carcinogens, toxins and drugs(1,2). Of the human CYP proteins, those of the CYP3A subfamily are of a major importance, since collectively, they are by far the most abundant of all the human CYP isoforms. Moreover, their substrate specificity is extremely broad; accordingly, many structurally diverse compounds are, exclusively or to some extent, substrates for CYP3A proteins. Based on the data available it is generally assumed that all CYP3A isoforms have similar substrate spectra; however, limited studies indicate the possibility of differences (3). All CYP3A isoforms are localized in organs of particular importance to drug disposition (gastrointestinal tract, kidney and liver).

[0003] At least three functional CYP3A proteins exist in humans. The CYP3A4 monooxygenase is the predominant cytochrome P450 in human liver and small bowel. The protein displays a broad substrate specificity and it metabolises more than 60% of all drugs that are currently in use, including contraceptive steroids, antidepressants, benzodiazepines, immunosuppressive agents, imidazole antimicrobics, and macrolide antibiotics (4,5). In addition, CYP3A4 plays a major role in the protection from environmental toxins. For example, the protein metabolizes aflatoxin B1, which has been implicated in the etiology of liver cancer, which is a major cause of premature death in many areas of Africa and Asia. Aflatoxin B1 is a mycotoxin produced by species of *Aspergillus*, and human exposure results principally from the ingestion of stored foodstuffs contaminated with the mold. Carcinogenicity is associated with its conversion to 8,9-oxide by the hepatic cytochrome P450-dependent monooxygenase system. Forrester et al. (6) found that the rates of metabolic activation of aflatoxin B1 were highly correlated with the level of proteins of the CYP3A gene family in the microsomes. Furthermore, Paolini et al. (7) found significant increases in CYP3A in the lungs of rats treated with high doses of beta-carotene. Consequently, it was proposed that correspondingly high levels of CYP3A4 in humans would predispose an individual to cancer risk from the bioactivated tobacco-smoke procarcinogens, thus explaining the co-carcinogenic effect of beta-carotene in smokers. All this implies that individual variation in the CYP3A4 activity could influence the efficacy of a variety of drug therapies as well as the individual predisposition to several major cancers caused by environmental carcinogens.

[0004] A considerable variation in the CYP3A4 content and catalytic activity has been, indeed, described in the general population. For example, the metabolic clearance of the gene substrates exhibits a unimodal distribution with up to 20-fold interindividual variability. The activities of the CYP3A4 protein in liver biopsies vary up to 30-fold (8). Furthermore, many common drugs alter the expression levels of the gene (induction or repression) and the extent of this phenomenon is individually variable. The inducers of CYP3A4 expression include commonly used drugs such as the glucocorticoid dexamethasone, the antibiotic rifampicin, and the antimycotic clotrimazole. The inducibility of CYP3A4 expression, combined with the diverse range of substrates, creates a potential for potentially harmful drug interactions involving this isozyme in patients undergoing therapies with multiple drugs.

[0005] CYP3A3 is a very closely related isoform to CYP3A4 (>more than 98% cDNA sequence similarity), but it is not known whether this reflects a separate gene product or an allelic variant. By contrast, CYP3A5 is a gene distinct from CYP3A4 and it is expressed polymorphically both in the adult and fetal liver and in the kidney and intestine. In adult Caucasians, the mRNA and the protein were detected in the liver of 10 to 30% of samples, while the protein was detected in the kidney and intestine of 70% of subjects (Ref. (9) and references therein). A point mutation described in the CYP3A5 gene which possibly results in the synthesis of an unstable protein, may account for the polymorphic expression of this enzyme (9). CYP3A7 is the third functional CYP3A isoform. CYP3A7 was originally isolated from a fetal liver but it was subsequently found in 54% of adult livers (10). Tests to estimate the inducibility and the activity of CYP3A isozymes in an individual patient would be of obvious relevance for the optimization of therapies with drugs which are their substrates, and for the prevention of the associated side effects. Direct estimates of the activities of CYP3A isozymes in liver biopsies are possible but impracticable for both ethical and cost reasons. The indirect *in vivo* tests of CYP3A4 activity such as the erythromycin breath test or the 6- β -hydroxycortisol test pose ethical problems such as the invasive administration of undesirable probe substances and they are obviously unsuited for routine testing. In addition, the lack of correlation between these tests questions their informative value regarding the CYP3A4 activity (11).

[0006] A major portion (83%) of the interindividual CYP3A4 variability has been attributed to genetic factors (12). The establishment of a genetic test for the activity of CYP3A4 and of the other CYP3A isozymes should be possible, assuming the prior identification of those factors. Genetic variance affecting the activity and the expression of CYP3A isozymes could be localized in the genes itself, or in one or more of their regulators. A comparison of the three originally published sequences of the best characterized CYP3A gene, CYP3A4, suggested the existence of polymorphisms affecting the amino acid sequence of the CYP3A4 protein (13). Unfortunately, this observation has not been, to our knowledge, confirmed in the general population. More recently, a polymorphism (CYP3A4-W) has been described in the nifedipine-specific response element of the CYP3A4 promoter (14). Its presence associates with a more advanced prostate tumor stage (14). Felix et al. (15) examined this polymorphism in 99 *de novo* and 30 treatment-related leukemias. In all treatment-related cases, there was prior exposure to one or more anticancer drugs metabolized by CYP3A, such as epipodophyllotoxins. These data suggest that individuals with the CYP3A4-W polymorphism may be at increased risk for treatment-related leukemia and that epipodophyllotoxin metabolism by CYP3A4 may contribute to the secondary cancer risk. At present it is unclear if the polymorphism influences the expressivity or inducibility of the CYP3A4 protein. A first published analysis suggests that it has no effect on the basal expression level of CYP3A4 (8). A point mutation was described in the CYP3A5 (9), whereas no mutations have been reported in CYP3A7.

[0007] Experiments with amino acid exchanges artificially introduced into the CYP3A4 gene indicate that the function of the family members may be quite sensitive to amino acid exchanges (16-21). Besides amino acid exchanges, silent polymorphisms and those localized in untranslated or intronic sequences also could influence the expression level of these genes. Alternatively, such polymorphisms could serve as markers for nearby, unidentified polymorphisms. This effect is known as linkage, i.e. defined polymorphisms serve as markers for phenotypes that they are not causative for.

[0008] A major breakthrough in the understanding of the CYP3A expression and inducibility took place in 1998 when three research groups independently showed that the expression of CYP3A4 is regulated by a member of the orphan nuclear receptor family termed PXR (pregnane X receptor), or PAR (22-24). Upon treatment with inducers of CYP3A4, PXR binds to the rifampicin/dexamethasone response element in the CYP3A4 promoter as a heterodimer with the 9-cis retinoic acid receptor (RXR). Northern blot analysis detected most abundant expression of hPXR in liver, colon, and small intestine, i.e. in the major organs expressing CYP3A4. The available evidence suggests that human PXR serves as a key transcriptional regulator of the CYP3A4 gene. A recent report describes the induction of CYP3A7 mediated by PXR suggesting that all members of the family may be regulated by this common transcriptional activator (25).

[0009] It is clear that naturally occurring mutations, if they exist can have effects on drug metabolism and efficacy of therapies with drugs, in particular in cancer treatment. It is unknown, however, how many of such variations exist, and with what frequency and at what positions in the human CYP3A4, CYP3A7 and hPXR genes.

Accordingly, means and methods for diagnosing and treating a variety of forms of individual drug intolerance and inefficacy of drug therapy which result from CYP3A4, CYP3A7 and/or hPXR gene polymorphisms that interfere e.g., with chemotherapeutic treatment of diseases, in particular cancer, was hitherto not available but are nevertheless highly desirable.

[0010] Thus, the technical problem of the present invention is to comply with the needs described above. The solution to this technical problem is achieved by providing the embodiments characterized in the claims.

Summary of the Invention

[0011] The present invention is based on the finding of novel, so far unknown variations in the nucleotide sequences of the CYP3A4, CYP3A7 and hPXR genes and the population distribution of these alleles. Based upon the knowledge

of these novel sequences diagnostic tests and reagents for such tests were designed for the specific detection and genotyping of CYP3A4, CYP3A7 and hPXR alleles in humans, including homozygous as well as heterozygous, frequent as well as rare alleles of the CYP3A4, CYP3A7 and hPXR genes. The determination of the CYP3A4, CYP3A7 and/or hPXR gene allele status of humans with such tests is useful for the optimization of therapies with the numerous substrates of CYP3A4 and CYP3A7. It may also be useful in the determination of the individual predisposition to several common cancers caused by environmental carcinogens.

In a first embodiment, the invention provides polynucleotides of molecular variant CYP3A4, CYP3A7 and hPXR genes and embodiments related thereto such as vectors, host cells, variant CYP3A4, CYP3A7 and hPXR proteins and methods for producing the same.

In yet another embodiment, the invention provides methods for identifying and obtaining drug candidates and inhibitors of CYP3A4, CYP3A7 and hPXR for therapy of disorders related to acquired drug hypo- or hypersensitivity as well as methods of diagnosing the status of such disorders.

In a further embodiment, the invention provides pharmaceutical and diagnostic compositions comprising the above-described polynucleotides, vectors containing the same, proteins, antibodies thereto, and drugs and inhibitors obtainable by the above-described method.

The pharmaceutical and diagnostic compositions, methods and uses of the invention are useful for the diagnosis and treatment of cancer and other diseases the therapy of which is dependent on drug treatment and tolerance. The novel variant forms of CYP3A4, CYP3A7 and hPXR genes according to the invention provide the potential for the development of a pharmacodynamic profile of drugs for a given patient.

Description of the invention

[0012] The finding and characterization of variations in the CYP3A4, CYP3A7 and hPXR genes, and diagnostic tests for the discrimination of different CYP3A4, CYP3A7 and hPXR alleles in human individuals provide a very potent tool for improving the therapy of diseases with drugs that are targets of the CYP3A4 or CYP3A7 gene product, and whose metabolism is therefore dependent on CYP3A4 or CYP3A7. The diagnosis of the individual allelic CYP3A4, CYP3A7 and hPXR status permits a more focused therapy, e.g., by opening the possibility to apply individual dose regimens of drugs. It may also be useful as prognostic tool for therapy outcome. Furthermore, diagnostic tests to genotype CYP3A4, CYP3A7 and hPXR, and novel CYP3A4, CYP3A7 and hPXR variants, will not only improve therapy with established drugs and help to correlate genotypes with drug activity or side effects. These tests and sequences also provide reagents for the development of novel inhibitors that specifically modulate the activity of the individual types of CYP3A4, CYP3A7 and hPXR. Expression in yeast, for example, of three allelic cDNAs encoding human liver CYP3A4 and methods for testing the binding properties and catalytic activities of their gene products have been described in (13).

[0013] Thus, the present invention provides a novel way to exploit molecular biology and pharmacological research for drug therapy while bypassing their potential detrimental effects which are due to expression of variant CYP3A4, CYP3A7 and hPXR genes.

[0014] Accordingly, the invention relates to a polynucleotide selected from the group consisting of:

(a) polynucleotides comprising a nucleotide sequence encoding the amino acid sequence encodable by a nucleotide sequence of SEQ ID NO: 86, 94 and/or 98;

(b) polynucleotides comprising a nucleotide sequence encoding a molecular variant of the cytochrome CYP3A4 protein by way of at least one amino acid deletion, addition and/or substitution at an amino acid position corresponding amino acid residue Gly56 in exon 3 of the CYP3A4 gene;

(c) polynucleotides comprising a nucleotide sequence encoding a molecular variant of the cytochrome CYP3A7 protein by way of at least one amino acid deletion, addition and/or substitution, preferably at an amino acid position corresponding amino acid residue Thr 409 in exon 11 of the CYP3A7 gene;

(d) polynucleotides comprising a nucleotide sequence of any one of SEQ ID NOS: 86, 87, 90, 91, 94, 95 or 108;

(e) polynucleotides comprising a nucleotide sequence of any one of SEQ ID NOS: 98, 99, 102, 103, 106 or 107; and

(f) polynucleotides comprising a nucleotide sequence encoding a CYP3A4 or CYP3A7 polypeptide or fragment thereof having an epitope comprising an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 86 and/or 94.

[0015] In the context of the present invention the term "molecular variant" CYP3A4, CYP3A7 or hPXR gene or protein as used herein means that said CYP3A4, CYP3A7 or hPXR gene or protein differs from the wild type CYP3A4, CYP3A7 or hPXR gene or protein by way of nucleotide substitution(s), addition(s) and/or deletion(s) (Genomic sequences of the CYP3A4, CYP3A7 gene are described, for example Bork, J Biol Chem 264 (1989), 910-9; Hashimoto, Eur J Biochem 218 (1993), 585-95; Beaune, Proc Natl Acad. Sci USA 83 (1986), 8064-8; Malowa, Proc Natl Acad Sci U S A 83 (1986), 5311-5; Accession numbers: M14096, J04449, X12387, M18907. The numbering of the polymorphisms refers to the

sequence M14096; for CYP3A7: the reference sequence is described in Komori, J Biochem (Tokyo) 105 (1989), 161-3; Accession number: gi4503232 and for the hPXR gene in Bertilsson, Proc Natl Acad Sci U S A. 95 (1998), 12208-13; Lehmann, J Clin Invest. 102 (1998), 1016-23; Accession numbers: AF061056, AF084645, AF084644. The numbering of the polymorphisms refers to the sequence AF084645). Preferably, said nucleotide substitution(s) result(s) in a corresponding change in the amino acid sequence of the CYP3A4, CYP3A7 or hPXR protein.

[0016] In accordance with the present invention, the mode and population distribution of novel so far unidentified genetic variations in the CYP3A4, CYP3A7 and hPXR gene have been analyzed by sequence analysis of relevant regions of the human CYP3A4, CYP3A7 and hPXR genes from many different individuals. It is a well known fact that genomic DNA of individuals, which harbor the individual genetic makeup of all genes, including CYP3A4, CYP3A7 and hPXR can easily be purified from individual blood samples. These individual DNA samples are then used for the analysis of the sequence composition of the CYP3A4, CYP3A7 and hPXR gene alleles that are present in the individual which provided the blood sample. The sequence analysis was carried out by PCR amplification of relevant regions of the CYP3A4, CYP3A7 and hPXR gene, subsequent purification of the PCR products, followed by automated DNA sequencing with established methods (ABI dyeterminator cycle sequencing).

One important parameter that had to be considered in the attempt to determine the individual CYP3A4, CYP3A7 and/or hPXR genotype and identify novel CYP3A4, CYP3A7 or hPXR variants by direct DNA-sequencing of PCR-products from human blood genomic DNA is the fact that each human harbors (usually, with very few abnormal exceptions) two gene copies of each autosomal gene (diploidy). Because of that, great care had to be taken in the evaluation of the sequences to be able to identify unambiguously not only homozygous sequence variations but also heterozygous variations. The details of the different steps in the identification and characterization of novel CYP3A4, CYP3A7 and hPXR gene polymorphisms (homozygous and heterozygous) are described in the examples below.

[0017] The mutations in the CYP3A4, CYP3A7 and hPXR genes detected in accordance with the present invention are illustrated in Figure 5 and 6, respectively (indicated by an arrow). The methods of the mutation analysis followed standard protocols and are described in detail in the examples. In general such methods to be used in accordance with the present invention for evaluating the phenotypic spectrum as well as the overlapping clinical characteristics with other forms of drug metabolism and altered tolerance to drugs in patients with mutations in the CYP3A4, CYP3A7 or hPXR gene encompass for example haplotype analysis, single-strand conformation polymorphism analysis (SSCA), PCR and direct sequencing. On the basis of thorough clinical characterization of many patients the phenotypes can then be correlated to these mutations as well as to mutations that had been described earlier.

[0018] As is evident to the person skilled in the art this new molecular genetic knowledge can now be used to exactly characterize the genotype of the index patient where a given drug takes an unusual effect and of his family.

[0019] Over the past 20 years, genetic heterogeneity has been increasingly recognized as a significant source of variation in drug response. Many scientific communications (Meyer, Ann. Rev. Pharmacol. Toxicol. 37 (1997), 269-296 and West, J. Clin. Pharmacol. 37 (1997), 635-648) have clearly shown that some drugs work better or may even be highly toxic in some patients than in others and that these variations in patient's responses to drugs can be related to molecular basis. This "pharmacogenomic" concept spots correlations between responses to drugs and genetic profiles of patient's (Marshall, Nature Biotechnology, 15 (1997), 954-957; Marshall, Nature Biotechnology, 15 (1997), 1249-1252).

[0020] In this context of population variability with regard to drug therapy, pharmacogenomics has been proposed as a tool useful in the identification and selection of patients which can respond to a particular drug without side effects. This identification/selection can be based upon molecular diagnosis of genetic polymorphisms by genotyping DNA from leukocytes in the blood of patient, for example, and characterization of disease (Bertz, Clin. Pharmacokinet. 32 (1997), 210-256; Engel, J. Chromatogra. B. Biomed. Appl. 678 (1996), 93-103). For the providers of health care, such as health maintenance organizations in the US and government public health services in many European countries, this pharmacogenomics approach can represent a way of both improving health care and reducing overheads because there is a large cost to unnecessary therapies, ineffective drugs and drugs with side effects.

[0021] The mutations in the variant CYP3A4, CYP3A7 and hPXR genes sometime result in amino acid deletion(s), insertion(s) and in particular in substitution(s) either alone or in combination. It is of course also possible to genetically engineer such mutations in wild type genes or other mutant forms. Methods for introducing such modifications in the DNA sequence of CYP3A4, CYP3A7 or hPXR gene are well known to the person skilled in the art; see, e.g., Sambrook, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory (1989) N.Y.

In a preferred embodiment of the invention, the above described polynucleotide encodes a variant CYP3A4, CYP3A7 or hPXR protein or fragment thereof, e.g., comprising one or more epitopes of the amino acid sequence encoded by SEQ ID NOS: 86 and 94.

[0022] For the investigation of the nature of the alterations in the amino acid sequence of the CYP3A4, CYP3A7 and hPXR proteins computer programs may be used such as BRASMOL that are obtainable from the Internet. Furthermore, folding simulations and computer redesign of structural motifs can be performed using other appropriate computer programs (Olszewski, Proteins 25 (1996), 286-299; Hoffman, Comput. Appl. Biosci. 11 (1995), 675-679). Computers

can be used for the conformational and energetic analysis of detailed protein models (Monge, J. Mol. Biol. 247 (1995), 995-1012; Renouf, Adv. Exp. Med. Biol. 376 (1995), 37-45). These analysis can be used for the identification of the influence of a particular mutation on binding and/or metabolism of drugs.

[0023] Usually, said amino acid deletion, addition or substitution in the amino acid sequence of the protein encoded by the polynucleotide of the invention is due to one or more nucleotide substitution, insertion or deletion, or any combinations thereof. Preferably said nucleotide substitution, insertion or deletion results in an amino acid substitution of Gly56 to Asp in exon 3 of the CYP3A4 gene and/or Thr409 to Arg in exon 11 of the CYP3A7 gene.

[0024] The polynucleotide of the invention may further comprise at least one nucleotide and optionally amino acid deletion, addition and/or substitution other than those specified hereinabove, for example those described in the prior art; e.g., (13). This embodiment of the present invention allows the study of synergistic effects of the mutations in the CYP3A4, CYP3A7 or hPXR gene on the pharmacological profile of drugs in patients who bear such mutant forms of the gene or similar mutant forms that can be mimicked by the above described proteins. It is expected that the analysis of said synergistic effects provides deeper insights into drug tolerant or sensitive phenotypes of certain forms of cancer and other diseases. From said deeper insight the development of diagnostic and pharmaceutical compositions related to cancer will greatly benefit.

[0025] Thus, in a preferred embodiment, the present invention relates to polynucleotides of molecular variant CYP3A4, CYP3A7 and hPXR genes, wherein the nucleotide deletion, addition and/or substitution result in altered expression of the variant CYP3A4, CYP3A7 or hPXR gene compared to the corresponding wild type gene.

[0026] The polynucleotide of the invention may be, e.g., DNA, cDNA, genomic DNA, RNA or synthetically produced DNA or RNA or a recombinantly produced chimeric nucleic acid molecule comprising any of those polynucleotides either alone or in combination. Preferably said polynucleotide is part of a vector, particularly plasmids, cosmids, viruses and bacteriophages used conventionally in genetic engineering that comprise a polynucleotide of the invention. Such vectors may comprise further genes such as marker genes which allow for the selection of said vector in a suitable host cell and under suitable conditions.

[0027] In a further preferred embodiment of the vector of the invention, the polynucleotide of the invention is operatively linked to expression control sequences allowing expression in prokaryotic or eukaryotic cells. Expression of said polynucleotide comprises transcription of the polynucleotide, preferably into a translatable mRNA. Regulatory elements ensuring expression in eukaryotic cells, preferably mammalian cells, are well known to those skilled in the art. They usually comprise regulatory sequences ensuring initiation of transcription and optionally poly-A signals ensuring termination of transcription and stabilization of the transcript. Additional regulatory elements may include transcriptional as well as translational enhancers. Possible regulatory elements permitting expression in prokaryotic host cells comprise, e.g., the *lac*, *trp* or *tac* promoter in *E. coli*, and examples for regulatory elements permitting expression in eukaryotic host cells are the *AOX1* or *GAL1* promoter in yeast or the CMV-, SV40-, RSV-promoter (Rous sarcoma virus), CMV-enhancer, SV40-enhancer or a globin intron in mammalian and other animal cells. Beside elements which are responsible for the initiation of transcription such regulatory elements may also comprise transcription termination signals, such as the SV40-poly-A site or the tk-poly-A site, downstream of the polynucleotide. In this context, suitable expression vectors are known in the art such as Okayama-Berg cDNA expression vector pcDV1 (Pharmacia), pCDM8, pRc/CMV, pcDNA1, pcDNA3 (In-vitro gene), pSPORT1 (GIBCO BRL). Preferably, said vector is an expression vector and/or a gene transfer or targeting vector. Expression vectors derived from viruses such as retroviruses, vaccinia virus, adeno-associated virus, herpes viruses, or bovine papilloma virus, may be used for delivery of the polynucleotides or vector of the invention into targeted cell population. Methods which are well known to those skilled in the art can be used to construct recombinant viral vectors; see, for example, the techniques described in Sambrook, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory (1989) N.Y. and Ausubel, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y. (1994). Alternatively, the polynucleotides and vectors of the invention can be reconstituted into liposomes for delivery to target cells.

[0028] The present invention furthermore relates to host cells transformed with a polynucleotide or vector of the invention. Said host cell may be a prokaryotic or eukaryotic cell; see supra. The polynucleotide or vector of the invention which is present in the host cell may either be integrated into the genome of the host cell or it may be maintained extrachromosomally. In this respect, it is also to be understood that the recombinant DNA molecule of the invention can be used for "gene targeting" and/or "gene replacement", for restoring a mutant gene or for creating a mutant gene via homologous recombination; see for example Mouellic, Proc. Natl. Acad. Sci. USA, 87 (1990), 4712-4716; Joyner, Gene Targeting, A Practical Approach, Oxford University Press.

The host cell can be any prokaryotic or eukaryotic cell, such as a bacterial, insect, fungal, plant, animal or human cell. Preferred fungal cells are, for example, those of the genus *Saccharomyces*, in particular those of the species *S. cerevisiae*. The term "prokaryotic" is meant to include all bacteria which can be transformed or transfected with a polynucleotide for the expression of a variant CYP3A4, CYP3A7 or hPXR protein or fragment thereof. Prokaryotic hosts may include gram negative as well as gram positive bacteria such as, for example, *E. coli*, *S. typhimurium*, *Serratia marcescens* and *Bacillus subtilis*. A polynucleotide coding for a mutant form of CYP3A4, CYP3A7 and hPXR variant proteins

can be used to transform or transfect the host using any of the techniques commonly known to those of ordinary skill in the art. Methods for preparing fused, operably linked genes and expressing them in bacteria or animal cells are well-known in the art (Sambrook, *supra*). The genetic constructs and methods described therein can be utilized for expression of variant CYP3A4, CYP3A7 and hPXR proteins in, e.g., prokaryotic hosts. In general, expression vectors containing promoter sequences which facilitate the efficient transcription of the inserted polynucleotide are used in connection with the host. The expression vector typically contains an origin of replication, a promoter, and a terminator, as well as specific genes which are capable of providing phenotypic selection of the transformed cells. The transformed prokaryotic hosts can be grown in fermentors and cultured according to techniques known in the art to achieve optimal cell growth. The proteins of the invention can then be isolated from the grown medium, cellular lysates, or cellular membrane fractions. The isolation and purification of the microbially or otherwise expressed polypeptides of the invention may be by any conventional means such as, for example, preparative chromatographic separations and immunological separations such as those involving the use of monoclonal or polyclonal antibodies.

[0029] Thus, in a further embodiment the invention relates to a method for the production of variant CYP3A4, CYP3A7 and hPXR proteins and fragments thereof comprising culturing a host cell as defined above under conditions allowing the expression of the protein and recovering the produced protein or fragment from the culture.

[0030] In another embodiment the present invention relates to a method for producing cells capable of expressing a variant CYP3A4, CYP3A7 and/or hPXR gene comprising genetically engineering cells with the polynucleotide or with the vector of the invention. The cells obtainable by the method of the invention can be used, for example, to test drugs according to the methods described in Sambrook, Fritsch, Maniatis (1989). *Molecular cloning: a laboratory manual*. Cold Spring Harbour Laboratory press, Cold Spring Harbour; Peyronneau, *Eur J Biochem* 218 (1993), 355-61; Yamazaki, *Carcinogenesis* 16 (1995), 2167-2170. Furthermore, the cells can be used to study known drugs and unknown derivatives thereof for their ability to complement loss of drug efficacy caused by mutations in the CYP3A4, CYP3A7 or hPXR gene. For these embodiments the host cells preferably lack a wild type allele, preferably both alleles of the CYP3A4, CYP3A7 and/or hPXR gene and/or have at least one mutated from thereof. Alternatively, strong overexpression of a mutated allele over the normal allele and comparison with a recombinant cell line overexpressing the normal allele at a similar level may be used as a screening and analysis system. The cells obtainable by the above-described method may also be used for the screening methods referred to herein below.

[0031] Furthermore, the invention relates to variant CYP3A4, CYP3A7 and hPXR proteins and fragments thereof encoded by a polynucleotide according to the invention or obtainable by the above-described methods or from cells produced by the method described above. In this context it is also understood that the variant CYP3A4, CYP3A7 and hPXR proteins according to the invention may be further modified by conventional methods known in the art. By providing the variant CYP3A4, CYP3A7 and hPXR proteins according to the present invention it is also possible to determine the portions relevant for their biological activity or inhibition of the same.

[0032] The present invention furthermore relates to antibodies specifically recognizing a variant CYP3A4, CYP3A7 or hPXR protein according to the invention. Advantageously, the antibody specifically recognizes an epitope containing one or more amino acid substitution(s) as defined above.

Antibodies against the variant CYP3A4, CYP3A7 or hPXR protein of the invention can be prepared by well known methods using a purified protein according to the invention or a (synthetic) fragment derived therefrom as an antigen. Monoclonal antibodies can be prepared, for example, by the techniques as originally described in Köhler and Milstein, *Nature* 256 (1975), 495, and Galfré, *Meth. Enzymol.* 73 (1981), 3, which comprise the fusion of mouse myeloma cells to spleen cells derived from immunized mammals. The antibodies can be monoclonal antibodies, polyclonal antibodies or synthetic antibodies as well as fragments of antibodies, such as Fab, Fv or scFv fragments etc. Furthermore, antibodies or fragments thereof to the aforementioned polypeptides can be obtained by using methods which are described, e.g., in Harlow and Lane "Antibodies, A Laboratory Manual", CSH Press, Cold Spring Harbor, 1988. These antibodies can be used, for example, for the immunoprecipitation and immunolocalization of the variant CYP3A4, CYP3A7 and hPXR proteins of the invention as well as for the monitoring of the presence of such variant CYP3A4, CYP3A7 and hPXR proteins, for example, in transgenic organisms, and for the identification of compounds interacting with the proteins according to the invention. For example, surface plasmon resonance as employed in the BIAcore system can be used to increase the efficiency of phage antibodies which bind to an epitope of the protein of the invention (Schier, *Human Antibodies Hybridomas* 7 (1996), 97-105; Malmborg, *J. Immunol. Methods* 183 (1995), 7-13).

[0033] Furthermore, the present invention relates to nucleic acid molecules which represent or comprise the complementary strand of any of the above described polynucleotides or a part thereof, thus comprising at least one nucleotide difference compared to the corresponding wild type CYP3A4, CYP3A7 and hPXR gene nucleotide sequences specified by the above described nucleotide substitutions, deletions and additions. Such a molecule may either be a deoxyribonucleic acid or a ribonucleic acid. Such molecules comprise, for example, antisense RNA. These molecules may furthermore be linked to sequences which when transcribed code for a ribozyme thereby producing a ribozyme which specifically cleaves transcripts of polynucleotides according to the invention.

[0034] Furthermore, the present invention relates to a vector comprising a nucleic acid molecule according to the

invention. Examples for such vectors are described above. Preferably, the nucleic acid molecule present in the vector is operatively linked to regulatory elements permitting expression in prokaryotic or eukaryotic host cells; see supra.

[0035] The present invention also relates to a method for the production of a transgenic non-human animal, preferably transgenic mouse, comprising introduction of a polynucleotide or vector of the invention into a germ cell, an embryonic cell, stem cell or an egg or a cell derived therefrom. The non-human animal can be used in accordance with the method of the invention described below and may be a non-transgenic healthy animal, or may have a disorder, preferably a disorder caused by at least one mutation in the CYP3A4, CYP3A7 and/or hPXR gene. Such transgenic animals are well suited for, e.g., pharmacological studies of drugs in connection with variant forms of the above described variant CYP3A4, CYP3A7 and hPXR proteins since these proteins or at least their functional domains are conserved between species in higher eukaryotes, particularly in mammals. Production of transgenic embryos and screening of those can be performed, e.g., as described by A. L. Joyner Ed., Gene Targeting, A Practical Approach (1993), Oxford University Press. The DNA of the embryos can be analyzed using, e.g., Southern blots with an appropriate probe.

[0036] The invention also relates to transgenic non-human animals such as transgenic mouse, rats, hamsters, dogs, monkeys, rabbits, pigs, *C. elegans* and fish such as torpedo fish comprising a polynucleotide or vector of the invention or obtained by the method described above, preferably wherein said polynucleotide or vector is stably integrated into the genome of said non-human animal, preferably such that the presence of said polynucleotide or vector leads to the expression of the variant CYP3A4, CYP3A7 and/or hPXR gene of the invention. It may have one or several copies of the same or different polynucleotides of the variant CYP3A4, CYP3A7 or hPXR gene. This animal has numerous utilities, including as a research model for drug tolerability and therefore, presents a novel and valuable animal in the development of therapies, treatment, etc. for diseases caused by deficiency or failure of drug metabolism in the cell. Accordingly, in this instance, the mammal is preferably a laboratory animal such as a mouse or rat.

[0037] Preferably, the transgenic non-human animal of the invention further comprises at least one inactivated wild type allele of the CYP3A4, CYP3A7 and/or hPXR gene. This embodiment allows for example the study of the interaction of various variant forms of CYP3A4, CYP3A7 and hPXR proteins. It might be also desirable to inactivate CYP3A4, CYP3A7 and/or hPXR gene expression or function at a certain stage of development and/or life of the transgenic animal. This can be achieved by using, for example, tissue specific, developmental and/or cell regulated and/or inducible promoters which drive the expression of, e.g., an antisense or ribozyme directed against the RNA transcript of the CYP3A4, CYP3A7 or hPXR gene; see also supra. A suitable inducible system is for example tetracycline-regulated gene expression as described, e.g., by Gossen and Bujard (Proc. Natl. Acad. Sci. 89 USA (1992), 5547-5551) and Gossen et al. (Trends Biotech. 12 (1994), 58-62). Similar, the expression of the variant CYP3A4, CYP3A7 and hPXR gene may be controlled by such regulatory elements.

[0038] With the variant CYP3A4, CYP3A7 and hPXR polynucleotides and proteins and vectors of the invention, it is now possible to study *in vivo* and *in vitro* the efficiency of drugs in relation to particular mutations in the CYP3A4, CYP3A7 or hPXR gene of a patient and the affected phenotype. Furthermore, the variant CYP3A4, CYP3A7 and hPXR proteins of the invention can be used to determine the pharmacological profile of drugs and for the identification and preparation of further drugs which may be more effective for the treatment of, e.g., cancer, in particular for the amelioration of certain phenotypes caused by the respective mutations such as those described above.

[0039] Thus, a particular object of the present invention concerns drug/pro-drug selection and formulation of pharmaceutical compositions for the treatment of diseases which are amenable to chemotherapy taking into account the polymorphism of the variant form of the CYP3A4, CYP3A7 or hPXR gene that cosegregates with the affected phenotype of the patient to be treated. This allows the safe and economic application of drugs which for example were hitherto considered not appropriate for therapy of, e.g., cancer due to either their side effects in some patients and/or their unreliable pharmacological profile with respect to the same or different phenotype(s) of the disease. The means and methods described herein can be used, for example, to improve dosing recommendations and allows the prescriber to anticipate necessary dose adjustments depending on the considered patient group.

[0040] In a further embodiment the present invention relates to a method of identifying and obtaining an CYP3A4, CYP3A7 or hPXR inhibitor capable of modulating the activity of a molecular variant of the CYP3A4, CYP3A7 or hPXR gene or its gene product comprising the steps of

- (a) contacting the variant CYP3A4, CYP3A7 or hPXR protein or a cell expressing a molecular variant gene comprising a polynucleotide of the invention in the presence of components capable of providing a detectable signal in response to drug metabolism, with a compound to be screened under conditions to permit CYP3A4 or CYP3A7 mediated drug metabolism, and
- (b) detecting the presence or absence of a signal or increase of a signal generated from the metabolized drug, wherein the presence or increase of the signal is indicative for a putative inhibitor.

[0041] The term "compound" in a method of the invention includes a single substance or a plurality of substances which may or may not be identical.

Said compound(s) may be chemically synthesized or produced via microbial fermentation but can also be comprised in, for example, samples, e.g., cell extracts from, e.g., plants, animals or microorganisms. Furthermore, said compounds may be known in the art but hitherto not known to be useful as an inhibitor, respectively. The plurality of compounds may be, e.g., added to the culture medium or injected into a cell or non-human animal of the invention.

If a sample containing (a) compound(s) is identified in the method of the invention, then it is either possible to isolate the compound from the original sample identified as containing the compound, in question or one can further subdivide the original sample, for example, if it consists of a plurality of different compounds, so as to reduce the number of different substances per sample and repeat the method with the subdivisions of the original sample.

[0042] It can then be determined whether said sample or compound displays the desired properties, for example, by the methods described herein or in the literature (e.g. (13) and Lehmann, J Clin Invest 102 (1998), 1016-23). Depending on the complexity of the samples, the steps described above can be performed several times, preferably until the sample identified according to the method of the invention only comprises a limited number of or only one substance (s). Preferably said sample comprises substances of similar chemical and/or physical properties, and most preferably said substances are identical. The methods of the present invention can be easily performed and designed by the person skilled in the art, for example in accordance with other cell based assays described in the prior art or by using and modifying the methods as described herein. Furthermore, the person skilled in the art will readily recognize which further compounds and/or enzymes may be used in order to perform the methods of the invention, for example, enzymes, if necessary, that convert a certain compound into the precursor which in turn represents a substrate for the CYP3A4 or CYP3A7 protein. Such adaptation of the method of the invention is well within the skill of the person skilled in the art and can be performed without undue experimentation.

[0043] Suitable assays which can be employed in accordance with the present invention are described, for example, in Hashimoto, Eur J Biochem 218 (1993), 585-95 wherein transfection assays with chimeric CYP3A4 genes in HepG2 cells are described. Similarly, the variant CYP3A4, CYP3A7 and/or hPXR genes can be expressed or co-expressed in HepG2 cells and analyzed for their transcriptional activity and catalytic properties of CYP3A4 or CYP3A7. Such an assay can also be used for studying the catalytic properties of the CYP3A4 and CYP3A7 on its substrates such as steroids (testosterone, progesterone, androstenedione, cortisol, 17 β -oestradiol, 17 α -ethynyoestradiol), antibiotics (erythromycin), immunosuppressive (cyclosporine A), benzodiazepine (midazolam), benzothiazepine derivatives (diltiazem, triazolam), and nifedipine. In particular, such tests are useful to add in predicting whether a given drug will interact in an individual carrying the respective variant CYP3A4, CYP3A7 and/or hPXR gene. A suitable expression system which can be employed in accordance with above described methods of the present invention is also described in (22). In addition heterologous expression systems such as yeast can be used in order to study the stability, binding properties and catalytic activities of the gene products of the variant CYP3A4, CYP3A7 and hPXR genes compared to the corresponding wild type gene product. As mentioned before, the molecular variant CYP3A4, CYP3A7 and hPXR genes and their gene products, particularly when employed in the above described methods, can be used for pharmacological and toxicological studies of the metabolism of drugs. Preferred drugs to be tested in accordance with the methods of the present invention comprise those described above and include, but are not limited to nifedipine, erythromycin, troleandomycin, quinidine, cyclosporin A, 17 α -ethynylestradiol, lidocaine, diltiazem, dexamethasone, RU486, see also supra.

Compounds which can be used in accordance with the present invention include peptides, proteins, nucleic acids, antibodies, small organic compounds, ligands, peptidomimetics, PNAs and the like. Said compounds can also be functional derivatives or analogues of known drugs such as from those described above. Methods for the preparation of chemical derivatives and analogues are well known to those skilled in the art and are described in, for example, Beilstein, Handbook of Organic Chemistry, Springer edition New York Inc., 175 Fifth Avenue, New York, N.Y. 10010 U.S.A. and Organic Synthesis, Wiley, New York, USA. Furthermore, said derivatives and analogues can be tested for their effects according to methods known in the art or as described. Furthermore, peptide mimetics and/or computer aided design of appropriate drug derivatives and analogues can be used, for example, according to the methods described below. Such analogs comprise molecules having as the basis structure of known CYP3A4 and CYP3A7-substrates and/or inhibitors and/or modulators; see infra.

Appropriate computer programs can be used for the identification of interactive sites of a putative inhibitor and the CYP3A4, CYP3A7 or hPXR protein of the invention by computer assistant searches for complementary structural motifs (Fassina, Immunomethods 5 (1994), 114-120). Further appropriate computer systems for the computer aided design of protein and peptides are described in the prior art, for example, in Berry, Biochem. Soc. Trans. 22 (1994), 1033-1036; Wodak, Ann. N. Y. Acad. Sci. 501 (1987), 1-13; Pabo, Biochemistry 25 (1986), 5987-5991. The results obtained from the above-described computer analysis can be used in combination with the method of the invention for, e.g., optimizing known inhibitors. Appropriate peptidomimetics and other inhibitors can also be identified by the synthesis of peptidomimetic combinatorial libraries through successive chemical modification and testing the resulting compounds, e.g., according to the methods described herein. Methods for the generation and use of peptidomimetic combinatorial libraries are described in the prior art, for example in Ostresh, Methods in Enzymology 267 (1996),

220-234 and Dorner, Bioorg. Med. Chem. 4 (1996), 709-715. Furthermore, the three-dimensional and/or crystallographic structure of inhibitors and the CYP3A4, CYP3A7 or hPXR protein of the invention can be used for the design of peptidomimetic drugs (Rose, Biochemistry 35 (1996), 12933-12944; Rutenberg, Bioorg. Med. Chem. 4 (1996), 1545-1558).

5 [0044] In summary, the present invention provides methods for identifying and obtaining compounds which can be used in specific doses for the treatment of specific forms of diseases, e.g., cancer the chemotherapy of which is complicated by malfunctions of the CYP3A4, CYP3A7 or hPXR gene often resulting in an altered activity or level of drug metabolism or sensitive phenotype.

[0045] In a preferred embodiment of the method of the invention said cell is a cell of or, obtained by the method of the invention or is comprised in the above-described transgenic non-human animal.

10 [0046] In a further embodiment the present invention relates to a method of identifying and obtaining an CYP3A4, CYP3A7 or hPXR inhibitor capable of modulating the activity of a molecular variant of the CYP3A4, CYP3A7 or hPXR gene or its gene product comprising the steps of

15 (a) contacting the variant CYP3A4, CYP3A7 or hPXR protein of the invention with a first molecule known to be bound by CYP3A4, CYP3A7 or hPXR protein to form a first complex of said protein and said first molecule;

(b) contacting said first complex with a compound to be screened; and

(c) measuring whether said compound displaces said first molecule from said first complex.

20 [0047] Advantageously, in said method said measuring step comprises measuring the formation of a second complex of said protein and said inhibitor candidate. Preferably, said measuring step comprises measuring the amount of said first molecule that is not bound to said protein.

[0048] In a particularly preferred embodiment of the above-described method of said first molecule is nifedipine, rifampicine or corticosterone. Furthermore, it is preferred that in the method of the invention said first molecule is labeled, e.g., with a radioactive or fluorescent label.

25 [0049] In a still further embodiment the present invention relates to a method of diagnosing a disorder related to the presence of a molecular variant CYP3A4, CYP3A7 or hPXR gene or susceptibility to such a disorder comprising

(a) determining the presence of a polynucleotide of the invention in a sample from a subject; and/or

30 (b) determining the presence of a variant form of CYP3A4, CYP3A7 or hPXR protein, for example, with the antibody of the invention.

[0050] In accordance with this embodiment of the present invention, the method of testing the status of a disorder or susceptibility to such a disorder can be effected by using a polynucleotide or a nucleic acid molecule of the invention, e.g., in the form of a Southern or Northern blot or *in situ* analysis. Said nucleic acid sequence may hybridize to a coding region of either of the genes or to a non-coding region, e.g. intron. In the case that a complementary sequence is employed in the method of the invention, said nucleic acid molecule can again be used in Northern blots. Additionally, said testing can be done in conjunction with an actual blocking, e.g., of the transcription of the gene and thus is expected to have therapeutic relevance. Furthermore, a primer or oligonucleotide can also be used for hybridizing to one of the above-mentioned CYP3A4, CYP3A7 or hPXR genes or corresponding mRNAs. The nucleic acids used for hybridization can, of course, be conveniently labeled by incorporating or attaching, e.g., a radioactive or other marker. Such markers are well known in the art. The labeling of said nucleic acid molecules can be effected by conventional methods. Additionally, the presence or expression of variant CYP3A4, CYP3A7 and hPXR genes can be monitored by using a primer pair that specifically hybridizes to either of the corresponding nucleic acid sequences and by carrying out a PCR reaction according to standard procedures. Specific hybridization of the above mentioned probes or primers preferably occurs at stringent hybridization conditions. The term "stringent hybridization conditions" is well known in the art; see, for example, Sambrook et al., "Molecular Cloning,

[0051] A Laboratory Manual" second ed., CSH Press, Cold Spring Harbor, 1989; "Nucleic Acid Hybridisation, A Practical Approach", Hames and Higgins eds., IRL Press, Oxford, 1985. Furthermore, the mRNA, cRNA, cDNA or genomic DNA obtained from the subject may be sequenced to identify mutations which may be characteristic fingerprints of mutations in the CYP3A4, CYP3A7 and hPXR gene. The present invention further comprises methods wherein such a fingerprint may be generated by RFLPs of DNA or RNA obtained from the subject, optionally the DNA or RNA may be amplified prior to analysis, the methods of which are well known in the art. RNA fingerprints may be performed by, for example, digesting an RNA sample obtained from the subject with a suitable RNA-Enzyme, for example RNase T₁, RNase T₂ or the like or a ribozyme and, for example, electrophoretically separating and detecting the RNA fragments as described above. Further modifications of the above-mentioned embodiment of the invention can be easily devised by the person skilled in the art, without any undue experimentation from this disclosure; see, e.g., the examples. An additional embodiment of the present invention relates to a method wherein said determination is effected by employing

an antibody of the invention or fragment thereof. The antibody used in the method of the invention may be labeled with detectable tags such as a histidine flags or a biotin molecule.

[0052] In a preferred embodiment of the present invention, the above described methods comprise PCR, ligase chain reaction, restriction digestion, direct sequencing, nucleic acid amplification techniques, hybridization techniques or immunoassays (Sambrook et al., loc. cit. CSH cloning, Harlow and Lane loc. cit. CSH antibodies).

[0053] In a preferred embodiment of the method of the present invention said disorder is cancer.

[0054] In a further embodiment of the above-described method, a further step comprising administering to the subject a medicament to abolish or alleviate said variations in the CYP3A4, CYP3A7 or hPXR gene in accordance with all applications of the method of the invention allows treatment of a given disease before the onset of clinical symptoms due to the phenotype response caused by the CYP3A4, CYP3A7 or hPXR gene.

[0055] In a preferred embodiment of the method of the invention said medicament are chemotherapeutic agents such as substrates of CYP3A4: paclitaxen (Eur J Drug Metab Pharmacokinet 23 (1998), 417-24), tamoxifen and toremifene (Drug Metab Dispos 27(1999), 681-8; Clin Pharmacol Ther 64 (1998), 648-54; Clin Pharmacol Ther 57 (1995), 628-35), trofosfamide (Cancer Chemother Pharmacol 44(1999), 327-334), cyclophosphamide and ifosfamide (Drug Metab Dispos 27 (1999), 655-66; Cancer Res 58 (1998), 4391-401; Br J Clin Pharmacol 40 (1995), 523-30), taxotere (Pharmacogenetics 8 (1998), 391-401; Clarke, Clin Pharmacokinet 36 (1999), 99-114).

[0056] In another preferred embodiment of the above-described methods, said method further comprises introducing

(i) a functional and expressible wild type CYP3A4, CYP3A7 or hPXR gene or

(ii) a nucleotide acid molecule or vector of the invention into cells.

[0057] In this context and as used throughout this specification, "functional" CYP3A4, CYP3A7 and hPXR gene means a gene wherein the encoded protein having part or all of the primary structural conformation of the wild type CYP3A4, CYP3A7 and hPXR protein, i.e. possessing the biological property of metabolizing drugs and controlling the CYP3A4, CYP3A7 gene, respectively. This embodiment of the present invention is suited for therapy of cancer in particular in humans. Detection of the expression of a variant CYP3A4 or CYP3A7 and/or hPXR gene would allow the conclusion that said expression is interrelated to the generation or maintenance of a corresponding phenotype of the disease. Accordingly, a step would be applied to reduce the expression level to low levels or abolish the same. This can be done, for example, by at least partial elimination of the expression of the mutant gene by biological means, for example, by the use of ribozymes, antisense nucleic acid molecules, intracellular antibodies or the above described inhibitors against the variant forms of these CYP3A4, CYP3A7 and/or hPXR proteins. Furthermore, pharmaceutical products may be developed that reduce the expression levels of the corresponding mutant proteins and genes.

[0058] In a further embodiment the invention relates to a method for the production of a pharmaceutical composition comprising the steps of any one of the above described methods and synthesizing and/or formulating the compound identified in step (b) or a derivative or homologue thereof in a pharmaceutically acceptable form. The therapeutically useful compounds identified according to the method of the invention may be formulated and administered to a patient as discussed above. For uses and therapeutic doses determined to be appropriate by one skilled in the art see infra.

[0059] Furthermore, the present invention relates to a method for the preparation of a pharmaceutical composition comprising the steps of the above-described methods; and formulating a drug or pro-drug in the form suitable for therapeutic application and preventing or ameliorating the disorder of the subject diagnosed in the method of the invention.

[0060] Drugs or pro-drugs after their *in vivo* administration are metabolized in order to be eliminated either by excretion or by metabolism to one or more active or inactive metabolites (Meyer, J. Pharmacokinet. Biopharm. 24 (1996), 449-459). Thus, rather than using the actual compound or inhibitor identified and obtained in accordance with the methods of the present invention a corresponding formulation as a pro-drug can be used which is converted into its active in the patient. Precautionary measures that may be taken for the application of pro-drugs and drugs are described in the literature; see, for review, Ozama, J. Toxicol. Sci. 21 (1996), 323-329).

[0061] In a preferred embodiment of the method of the present invention said drug or prodrug is a derivative of a medicament as defined hereinbefore.

[0062] In a still further embodiment the present invention relates to an inhibitor identified or obtained by the method described hereinbefore. Preferably, the inhibitor binds specifically to the variant CYP3A4, CYP3A7 or hPXR protein of the invention. The antibodies, nucleic acid molecules and inhibitors of the present invention preferably have a specificity at least substantially identical to binding specificity of the natural ligand or binding partner of the CYP3A4, CYP3A7 or hPXR protein of the invention. An antibody or inhibitor can have a binding affinity to the CYP3A4, CYP3A7 or hPXR protein of the invention of at least 10^5 M^{-1} , preferably higher than 10^7 M^{-1} and advantageously up to 10^{10} M^{-1} in case CYP3A4, CYP3A7 or hPXR activity should be repressed. Hence, in a preferred embodiment, a suppressive antibody or inhibitor of the invention has an affinity of at least about 10^{-7} M , preferably at least about 10^{-9} M and most preferably at last about 10^{-11} M .

[0063] Furthermore, the present invention relates to the use of an oligo- or polynucleotide for the detection of a polynucleotide of the invention and/or for genotyping of corresponding individual CYP3A4, CYP3A7 or hPXR alleles. Preferably, said oligo- or polynucleotide is a polynucleotide or a nucleic acid molecule of the invention described before.

[0064] In a particular preferred embodiment said oligonucleotide is about 15 to 50, preferably 20 to 40, more preferably 20 to 30 nucleotides in length and comprises the nucleotide sequence of any one of SEQ ID NOS: 1 to 107 or a complementary sequence.

[0065] Hence, in a still further embodiment, the present invention relates to a primer or probe consisting of an oligonucleotide as defined above. In this context, the term "consisting of" means that the nucleotide sequence described above and employed for the primer or probe of the invention does not have any further nucleotide sequences of the CYP3A4, CYP3A7 or hPXR gene immediately adjacent at its 5' and/or 3' end. However, other moieties such as labels, e.g., biotin molecules, histidin flags, antibody fragments, colloidal gold, etc. as well as nucleotide sequences which do not correspond to the CYP3A4, CYP3A7 or hPXR gene may be present in the primer and probes of the present invention. Furthermore, it is also possible to use the above described particular nucleotide sequences and to combine them with other nucleotide sequences derived from the CYP3A4, CYP3A7 or hPXR gene wherein these additional nucleotide sequences are interspersed with moieties other than nucleic acids or wherein the nucleic acid does not correspond to nucleotide sequences of the CYP3A4, CYP3A7 or hPXR gene. Furthermore, it is evident to the person skilled in the art that the oligonucleotide can be modified, for example, by thio-phosphate-backbones and/or base analogs well known in the art (Flanagan, Proc. Natl. Acad. Sci. USA 96 (1999), 3513-8; Witters, Breast Cancer Res. Treat. 53 (1999), 41-50; Hawley, Antisense Nucleic Acid Drug Dev. 9 (1999), 61-9; Peng Ho, Brain Res. Mol. Brain Res. 62 (1998), 1-11; Spiller, Antisense Nucleic Acid Drug Dev. 8 (1998), 281-93; Zhang, J. Pharmacol. Exp. Ther. 278 (1996), 971-9; Shoji, Antimicrob. Agents Chemother. 40 (1996), 1670-5; Crooke, J. Pharmacol. Exp. Ther. 277 (1996), 923-37).

[0066] In addition, the present invention relates to the use of an antibody or a substance capable of binding specifically to the gene product of an CYP3A4, CYP3A7 or hPXR gene for the detection of the variant CYP3A4, CYP3A7 or hPXR protein of the invention, the expression of a molecular variant CYP3A4, CYP3A7 or hPXR gene comprising a polynucleotide of the invention and/or for distinguishing CYP3A4, CYP3A7 and hPXR alleles comprising a polynucleotide of the invention.

[0067] Moreover, the present invention relates to a composition, preferably pharmaceutical composition comprising the antibody, the nucleic acid molecule, the vector or the inhibitor of the present invention, and optionally a pharmaceutically acceptable carrier. These pharmaceutical compositions comprising, e.g., the inhibitor or pharmaceutically acceptable salts thereof may conveniently be administered by any of the routes conventionally used for drug administration, for instance, orally, topically, parenterally or by inhalation. Acceptable salts comprise acetate, methylester, HCl, sulfate, chloride and the like. The compounds may be administered in conventional dosage forms prepared by combining the drugs with standard pharmaceutical carriers according to conventional procedures. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation. It will be appreciated that the form and character of the pharmaceutically acceptable character or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. The pharmaceutical carrier employed may be, for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like. Exemplary of liquid carriers are phosphate buffered saline solution, syrup, oil such as peanut oil and olive oil, water, emulsions, various types of wetting agents, sterile solutions and the like. Similarly, the carrier or diluent may include time delay material well known to the art, such as glyceryl monostearate or glyceryl distearate alone or with a wax.

The dosage regimen will be determined by the attending physician and other clinical factors; preferably in accordance with any one of the above described methods. As is well known in the medical arts, dosages for any one patient depends upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently. Progress can be monitored by periodic assessment.

[0068] Furthermore, the use of pharmaceutical compositions which comprise antisense-oligonucleotides which specifically hybridize to RNA encoding mutated versions of a CYP3A4, CYP3A7 or hPXR gene according to the invention or which comprise antibodies specifically recognizing mutated CYP3A4, CYP3A7 or hPXR protein but not or not substantially the functional wild-type form is conceivable in cases in which the concentration of the mutated form in the cells should be reduced.

Thanks to the present invention the particular drug selection, dosage regimen and corresponding patients to be treated can be determined in accordance with the present invention. The dosing recommendations will be indicated in product labeling by allowing the prescriber to anticipate dose adjustments depending on the considered patient group, with information that avoids prescribing the wrong drug to the wrong patients at the wrong dose.

[0069] Furthermore, the present invention relates to a diagnostic composition or kit comprising any one of the afore-

described polynucleotides, vectors, host cells, variant CYP3A4, CYP3A7 and hPXR proteins, antibodies, inhibitors, nucleic acid molecules or the corresponding vectors of the invention, and optionally suitable means for detection.

The kit of the invention may contain further ingredients such as selection markers and components for selective media suitable for the generation of transgenic cells and animals. The kit of the invention may advantageously be used for carrying out a method of the invention and could be, inter alia, employed in a variety of applications, e.g., in the diagnostic field or as research tool. The parts of the kit of the invention can be packaged individually in vials or in combination in containers or multicontainer units. Manufacture of the kit follows preferably standard procedures which are known to the person skilled in the art. The kit or diagnostic compositions may be used for methods for detecting expression of a mutant form of CYP3A4, CYP3A7 or hPXR gene in accordance with any one of the above-described methods of the invention, employing, for example, immunoassay techniques such as radioimmunoassay or enzymeimmunoassay or preferably nucleic acid hybridization and/or amplification techniques such as those described herein before and in the examples.

[0070] Some genetic changes lead to altered protein conformational states. For example, some variant CYP3A4, CYP3A7 or hPXR proteins may possess a tertiary structure that renders them far less capable of facilitating drug metabolism and transcription initiation, respectively. Restoring the normal or regulated conformation of mutated proteins is the most elegant and specific means to correct these molecular defects, although it is difficult. Pharmacological manipulations thus may aim at restoration of wild-type conformation of the protein. Thus, the polynucleotides and encoded proteins of the present invention may also be used to design and/or identify molecules which are capable of activating the wild-type function of a CYP3A4, CYP3A7 or hPXR gene or protein.

[0071] In another embodiment the present invention relates to the use of a drug or prodrug for the preparation of a pharmaceutical composition for the treatment or prevention of a disorder diagnosed by the method described herein before.

Furthermore, the present invention relates to the use of an effective dose of a nucleic acid sequence encoding a functional and expressible wild type CYP3A4, CYP3A7 or hPXR protein for the preparation of a pharmaceutical composition for treating, preventing and/or delaying a disorder diagnosed by the method of the invention. A gene encoding a functional and expressible CYP3A4, CYP3A7 or hPXR protein can be introduced into the cells which in turn produce the protein of interest. Gene therapy, which is based on introducing therapeutic genes into cells by *ex-vivo* or *in-vivo* techniques is one of the most important applications of gene transfer. Suitable vectors and methods for *in-vitro* or *in-vivo* gene therapy are described in the literature and are known to the person skilled in the art; see, e.g., Giordano, Nature Medicine 2 (1996), 534-539; Schaper, Circ. Res. 79 (1996), 911-919; Anderson, Science 256 (1992), 808-813; Isner, Lancet 348 (1996), 370-374; Muhlhauser, Circ. Res. 77 (1995), 1077-1086; Wang, Nature Medicine 2 (1996), 714-716; WO94/29469; WO 97/00957 or Schaper, Current Opinion in Biotechnology 7 (1996), 635-640, and references cited therein. The gene may be designed for direct introduction or for introduction via liposomes, or viral vectors (e.g. adenoviral, retroviral) into the cell. Preferably, said cell is a germ line cell, embryonic cell, or egg cell or derived therefrom, most preferably said cell is a stem cell.

[0072] As is evident from the above, it is preferred that in the use of the invention the nucleic acid sequence is operatively linked to regulatory elements allowing for the expression and/or targeting of the CYP3A4, CYP3A7 or hPXR protein to specific cells. Suitable gene delivery systems that can be employed in accordance with the invention may include liposomes, receptor-mediated delivery systems, naked DNA, and viral vectors such as herpes viruses, retroviruses, adenoviruses, and adeno-associated viruses, among others. Delivery of nucleic acids to a specific site in the body for gene therapy may also be accomplished using a biolistic delivery system, such as that described by Williams (Proc. Natl. Acad. Sci. USA 88 (1991), 2726-2729). Standard methods for transfecting cells with recombinant DNA are well known to those skilled in the art of molecular biology, see, e.g., WO 94/29469; see also supra. Gene therapy may be carried out by directly administering the recombinant DNA molecule or vector of the invention to a patient or by transfecting cells with the polynucleotide or vector of the invention *ex vivo* and infusing the transfected cells into the patient.

[0073] In a preferred embodiment of the uses and methods of the invention, said disorder is cancer.

[0074] These and other embodiments are disclosed or are obvious from and encompassed by the description and examples of the present invention. Further literature concerning any one of the methods, uses and compounds to be employed in accordance with the present invention may be retrieved from public libraries, using for example electronic devices. For example the public database "Medline" may be utilized which is available on Internet, e.g. under <http://www.ncbi.nlm.nih.gov/PubMed/medline.html>. Further databases and addresses, such as <http://www.ncbi.nlm.nih.gov/>, <http://www.infobiogen.fr/>, http://www.fmi.ch/biology/research_tools.html, <http://www.tigr.org/>, are known to the person skilled in the art and can also be obtained using, e.g., <http://www.lycos.com>. An overview of patent information in biotechnology and a survey of relevant sources of patent information useful for retrospective searching and for current awareness is given in Berks, TIBTECH 12 (1994), 352-364.

[0075] The pharmaceutical and diagnostic compositions, uses, methods of the invention can be used for the diagnosis and treatment of all kinds of diseases hitherto unknown as being related to or dependent on variant CYP3A4,

CYP3A7 and hPXR genes. The compositions, methods and uses of the present invention may be desirably employed in humans, although animal treatment is also encompassed by the methods and uses described herein.

Brief description of the figures

[0076]

Figure 1: Differences in the genetic makeup influence the efficacy and safety of drug treatment.

Figure 2: A current model of the regulation of CYP3A4 by hPXR.

Figure 3: (A) Structure of the CYP3A4 gene as described in Ref. by Hashimoto, Eur Biochem 218 (1993) 585-95 and confirmed in this study. Coding regions are indicated as filled rectangles, the non-coding 5' untranslated region as a dashed rectangle. Arrowheads represent the positions of oligonucleotides used to screen the coding region of the gene (see Table 2 for the oligonucleotide sequences). (B) Determination of the exon flanking sequences. Double-headed arrows indicate genomic regions amplified by PCR. Single-headed arrows indicate sequences obtained by direct sequencing of BAC clones. The sequences of oligonucleotides shown in (B) are given in Table 1.

Figure 4: (A) Structure of the hPXR gene. Coding regions are indicated as filled rectangles, non-coding 5' and 3' untranslated regions as dashed rectangles. Arrowheads represent the positions of oligonucleotides used to screen the coding region of the gene (see Table 5 for the oligonucleotide sequences). (B) Elucidation of the genomic structure of hPXR. Double-headed arrows indicate genomic regions amplified by PCR. Oligonucleotides used to isolate an hPXR-containing BAC clone are shown in bold. Single-headed arrows indicate sequences obtained by direct sequencing of this clone. (C) Differential expression of hPXR transcripts in the liver (L) and small intestine (SI) as investigated by PCR amplification of tissue-derived cDNA pools. Exon 1b is expressed in both target tissues of the gene whereas exon 1a is expressed only in the liver. The sequences of oligonucleotides shown in (B) and (C) are given in Table 3.

Figure 5: Polymorphisms in the CYP3A4 and CYP3A7 genes. Numbering of polymorphic sites within the exons of CYP3A4 is based on the GenBank sequence M14096. Numbering of polymorphic sites within the exons of CYP3A7 is based on the GenBank sequence gi4503232.

Figure 6: Polymorphisms in the hPXR gene. Numbering of polymorphic sites within the exons of hPXR is based on the GenBank sequence AF084645.

Figure 7: An enzymatic test for the CYP3A7 exon 11 C1229G (Thr409Arg) polymorphism. (A) The mutation eliminates the unique AlwNI restriction site from the exon 11-containing fragment amplified with oligonucleotides 3A442F and 3A438R (arrowheads). (B) Genotyping of a wild-type (wt/wt) and a heterozygous (wt/C1229G) DNA sample by means of the AlwNI restriction digest.

Figure 8: Genomic sequences and polymorphisms in CYP3A4, CYP3A7 and hPXR genes. Primers used for the amplification and sequencing (Tables 1 and 3), as well as splice sites are underlined. Thick underlined are polymorphic sites and they are shown as the wild-type and variant base, separated by an arrow.

[0077] The invention will now be described by reference to the following examples which are merely illustrative and are not to be construed as a limitation of the scope of the present invention.

Examples

[0078] Genomic samples, isolated by standard techniques from 22 human livers were obtained from Prof. Urs Meyer, Biozentrum der Universität Basel. Liver samples were obtained under consideration of all legal, ethical and medical requirement of the Biozentrum der Universität Basel. Blood samples from 95 individuals were obtained and processed by ion exchange chromatography methods (Qiagen) to isolate DNA. Blood samples were obtained under consideration of all legal, ethical and medical requirement of Parexel International (Berlin).

Example 1: Genomic organization and oligonucleotides for the amplification of the coding regions of CYP3A4, CYP3A7 and hPXR

[0079] The genomic structure of CYP3A4 has been described in an earlier work (Hashimoto, Eur. J. Biochem. 218 (1993), 585-95); however, the published exon flanking sequences were too short to design oligonucleotides for exon amplification. In accordance with the present invention these sequences have been elucidated first by sequencing of PCR (Polymerase Chain Reaction)-amplified fragments containing parts of two neighboring exons and the intercalated intron. The primers used for the amplification of these fragments were derived from the published cDNA sequence (Beaune, Proc. Natl. Acad. Sci. USA 83 (1986), 8064-8, GenBank accession number M14096) upon consideration of the exon/intron organization of the gene (Table 1, Fig. 3). For exons flanked by larger introns, CYP3A4-containing bacterial artificial chromosome (BAC) clones (Control numbers 22300 and 22301) purchased from Genome Systems (St. Louis, MO, USA) were directly sequenced. The clones had been isolated by PCR using the CYP3A4PF and CYP3A4PR oligonucleotides (Table 1), which were derived from the promoter region of the gene (GenBank accession number D11131, Hashimoto, supra). The sequences thus obtained were used to design oligonucleotides for the amplification of the gene exons (Fig. 1). Their sequences, the amplification conditions, and the sizes of the resulting DNA fragments are given in Table 2. Besides the exon sequences, fragments amplified contain also some flanking intronic sequences, including the splice sites. The oligonucleotide 3A425R was derived from the non-coding part of CYP3A4 cDNA (exon 13, Beaune, supra, GenBank accession number M14096). The sequences of oligonucleotides to determine the exon/intron boundary of Exon 11 of CYP3A7 (3A720R and 3A721F) are shown in **bold** in Table 1.

In accordance with the present invention a similar strategy was applied to elucidate the genomic organization and to determine exon-flanking sequences of the CYP3A4 and CYP3A7 regulator, hPXR (Fig. 4A, B, Table 3). The gene consists of 10 exons and spans at least 19 kb of genomic DNA. The sequences at exon-intron junctions as well as exon and intron sizes are given in Table 4. Exons 1b and 1a are utilized alternately in the formation of hPXR transcripts. This is evidenced by the amplification of liver and intestine cDNA pools (Clontech) with primers derived from exons 1b, 1a, and 2 (Fig. 4C), followed by sequencing. In agreement with this observation, exon 1A lacks a 3' consensus splice site. Furthermore, exon 1B and 1A sequences correspond to the divergent 5' sequences of the two cDNA hPXR clones described by Bertilsson et al. (23) (GenBank accession numbers AF084645 and AF084644). The two transcripts are differentially expressed in the target tissues of hPXR. Exon 1b is expressed both in the liver and in the small intestine whereas exon 1a is expressed only in the latter tissue (Fig. 1B).

[0080] The sequences thus obtained were used to design oligonucleotides for amplification of the gene exons. Their composition and the sizes of the resulting DNA fragments are given in Table 5. Besides the exon sequences, fragments amplified contain also some flanking intronic sequences, including the splice sites, as well as some 5'- and 3'-UTR (untranslated region) sequences of the gene.

Example 2: Isolation of genomic DNA, amplification, purification and sequencing of CYP3A4, CYP3A7 and hPXR gene fragments

[0081] Genomic DNA was isolated using standard techniques from 22 liver samples and 95 blood samples obtained from unrelated Caucasians. Conditions for the amplification of CYP3A4, CYP3A7 and hPXR gene fragments by PCR are given in Tables 2 and 5, respectively. The complete sequences of the amplicons are given in Figure 8. The quality of amplicons was routinely checked by agarose gel electrophoresis. The fragments were then processed through PCR purification columns (Qiagen) which remove all the components of the PCR that could otherwise interfere with the subsequent sequencing reaction.

[0082] The sequencing reaction was performed using the dye-terminator method and the samples were then resolved on polyacrylamide gels (Perkin-Elmer 377 and 3700 sequencing machines). Both strands were routinely sequenced to assure high accuracy of the results and the detection of heterozygotes. The sequences were visually inspected for their quality and then analyzed for the presence of polymorphisms using the PHRED/PHRAP/POLYPHRED/CONSED software package (University of Washington, Seattle, USA).

Example 3: Polymorphisms in the CYP3A4 and CYP3A7 gene

[0083] In accordance with the present invention, 22 or more DNA samples were screened for mutations in exons 3, 4, 5, 7 and 9 of the CYP3A4 gene, and in exon 11 of the CYP3A7 gene. Three novel mutations were detected in the samples screened, two of them result in non-conservative amino acid exchanges (Fig. 5, Table 6, Table 8, Figure 8). The numbering of nucleotide polymorphisms within the CYP3A4 transcript, and of positions of the resulting amino acid exchanges, is based on GenBank sequence M14096. For CYP3A7 GenBank sequence gi 4503232 was used as reference.

- a G235A single nucleotide polymorphism (SNP) in exon 3 of CYP3A4 in 6 of the 234 chromosomes screened. The SNP results in the non-conservative amino acid exchange Gly→Asp at position 56 of the CYP3A4 protein.
- a G→T SNP in intron 7 of CYP3A4 in 4 out of 44 chromosomes screened. The SNP is localized at position 33 of the intron sequence (the G of the 5' consensus splice site GT is taken as position 1).
- a C1229G SNP in exon 11 of CYP3A7 in 17 out of 232 chromosomes screened. The SNP results in the non-conservative amino acid exchange Thr→Arg at position 409 of the CYP3A7 protein.

Example 4: Polymorphisms in the hPXR gene

[0084] In accordance with the present invention 22 DNA samples were screened for mutations in exons 1b, 2, 5/6, 7, 8, 9 and 9a of the hPXR gene. Three polymorphisms were detected in the samples screened (Fig. 6, Table 7, Table 8, Figure 8). The numbering of nucleotide polymorphisms within the hPXR transcript, and of positions of the resulting amino acid exchanges is based on GenBank hPXR sequence AF084645.

- A C149A SNP in exon 1b in 27 out of 44 chromosomes screened. Exon 1b is untranslated, i.e. the SNP has no effect on the amino acid sequence of the protein.
- a CC975TT SNP in exon 5/6 in 2 out of 44 chromosomes screened. The SNP is silent, i.e. it has no effect on the amino acid sequence of the protein.
- A C→T SNP in intron 7 in 8 out of 44 chromosomes screened. The SNP is localized at position 184 of the intron sequence (the G of the 5' consensus splice site GT is taken as position 1).

Example 5: An enzymatic test for the CYP3A7 exon 11 C1229G polymorphism

[0085] The C1229G polymorphism detected in exon 11 of CYP3A7 results in the loss of an AlwNI restriction site (Fig. 7A). In accordance with the present invention an AlwNI-based test was developed for the genotyping of the C1229G allele. An example is shown in Fig. 7B. A digest of the 404 bp genomic fragment amplified from a wild-type sample (wt/wt) with primers 3A742F and 3A738R (Table 2) generates two fragments of 316 bp and 88 bp, respectively. In a heterozygous sample (wt/C1229G), approximately half of the DNA remains undigested, due to the loss of the restriction site in the mutant allele.

[0086] Because population genetics enables a calculation of the expected frequency of homozygous vs. heterozygous alleles of a defined gene (Hardy Weinberg formula, $p^2 + 2pq + q^2 = 1$), it is also possible to confirm the predicted (with that formula) distribution of homozygous vs. heterozygous alleles and deviations with the experimental findings. This can serve as internal control and confirmation that a detected sequence deviation indeed represents a novel allele.

Table 1.

Oligonucleotides used to determine the exon/intron boundaries of the CYP3A4 gene and of the exon 11 of CYP3A7 (in bold).		
Name	Position	Sequence (5' - 3')
T7	BAC CS	TAATACGACTCACTATAGGG
3A43F	exon 2	GAACCCATTACATGGAC
3A46R	exon 4	TGATCATGTCAGGATCTG
3A47F	exon 4	GGTCAACAGCCTGTGCTG
3A48R	exon 5	TCCACTGGTGAAGGTTGG
3A49F	exon 5	GTGCCATCTCTATAGCTG
3A410R	exon 6	CTTCCCGCCTCAGATTTT
3A411F	exon 6	GAAATCTGAGGCGGGAAG
3A412R	exon 7	GGGTCTTGTGGATTGTTG
3A413F	exon 7	CAACAATCCACAAGACCC
3A414R	exon 8	GTGTATCTTCGAGGCGAC
3A415F	exon 8	CTTCCATTCTCATCCC

Table 1. (continued)

Oligonucleotides used to determine the exon/intron boundaries of the CYP3A4 gene and of the exon 11 of CYP3A7 (in bold).		
Name	Position	Sequence (5' - 3')
3A416R	exon 9	CCTTTGTGGGACTCAGTTTC
3A419F	exon 10	GCCACTCACCCCTGATGTC
3A720R	exon 11	ATCACCACCCACCCTTTG
3A721F	exon 11	CAAAGGGTGGGTGGTGAT
3A422R	exon 12	GAGAGCAAACCTCATGCC
3A423F	exon 12	GGCATGAGGTTTGCTCTC
3A424R	exon 13	GGTGCCATCCCTTGACTC
3A426R	exon 2	GCAGAGGTGTGGGCCCTG
3A4436F	intron 8	GGAGATCAAGGACCACGCTTGTC
3A441R	intron 10	CTTACGCTTCTGCCAGTAGCAACC
CYP3A4PF	promoter	AACAGGCGTGGAACACAAT
CYP3A4PR	promoter	CTTTCCTGCCCTGCACAG

[0087] Fifty ng of genomic DNA was added to a reaction mix (total volume 30 or 50 µl) containing 1x PCR buffer (Q=Qiagen, Cat.Nr. 1005479, or B2=Boehringer (currently Roche) Expand Long Template PCR Buffer number 2, Cat. Nr. 1742655), 0.25 µM each oligonucleotide (Metabion), 200 µM dNTPs, and 1 U of Taq polymerase (Qiagen). Amplifications were performed on a RoboCycler Gradient 96 (Stratagene) with an initial denaturation step of 2 min. at 94 °C followed by 32 amplification cycles of denaturation (40 sec., 94 °C), annealing (45 sec., temperatures 56-60 °C), and extension (60-150 sec., 72 °C). This was followed by a final extension step 5 min., 72 °C. The sequencing of PCR fragments and BAC clones was performed on a GeneAmp PCR System 9700 (Perkin-Elmer) using a dye-terminator DNA sequencing kit. (Perkin-Elmer, Cat.Nr. 4303154), according to manufacturers's instructions.

Table 2. CYP3A4 (exons 3, 4, 5, 7 and 9) and CYP3A7 (exon 11, in bold) polymorphism screen: oligonucleotide sequences, amplification conditions and fragment size.

Exon	Upstream Oligonucleotide		Downstream Oligonucleotide		Ann. Temp. (°C)	Product Size (bp)
	Name	Sequence (5'-3')	Name	Sequence (5'-3')		
1						
2						
3	3A450F	CCTCTAACTGCCAGCAAGTCTG	3A451R	GCGCTGAGACTGTCCTCTGTG	58	247
4	3A452F	AGTCTGGCTTCCTGGTTGGGCTC	3A437R	GAAGTGGACGTGGAACCTTCCTGGAC	58	293
5	3A428F	CTACAACCATGGAGACCTCC	3A429R	TACCTGTCCCCACCAGATTTC	58	236
6						
7	3A433F	GTCTGTCTTGACTGGACATGTGG	3A434R	GATGATGGTCACACATATCTTC	58	393
8						
9	3A436F	GGAGATCAAGGACCACGCTTGTG	3A447R	CTCATCATCCTCTGGAATACTTCCTGC	60	245
10						
11	3A742F	CCAGTATGAGTTGTTCTCTGG	3A738R	AGGCAGAAATATGCTTGAACCAGGC	58	404
12						
13						

[0088] Fifty ng of genomic DNA was added to a reaction mix containing 1x PCR buffer (Qiagen), 0.5 μ M oligonucleotides, 200 μ M dNTPs, and 1 U of Taq polymerase (Qiagen). Amplifications were performed on a RoboCycler Gradient 96 (Stratagene) with an initial denaturation step of 2 min. at 94 °C followed by 32 amplification cycles of denaturation (40 sec., 94 °C), annealing (45 sec., temperatures given above), and extension (60 sec., 72 °C). This was followed by a final extension step 5 min., 72 °C All sequencing reactions were performed on a GeneAmp PCR System 9700 (Perkin-Elmer) using a dye-terminator DNA sequencing kit (Perkin-Elmer, catalog number 4303154), according to manufacturers's instructions.

Table 3.

Oligonucleotides used to determine the structure and exon/intron boundaries of the hPXR gene.		
Name	Position	Sequence (5' - 3')
hPXR1F	exon 4	TCATGTCCGACGAGGCCG
hPXR4F	exon 5/6	CCCACATGGCTGACATGT
hPXR5F	exon 7	CCCATCGAGGACCAGATC
hPXR6R	exon 7	GTCTTCCAAGCAGTAGGA
hPXR7R	exon 8	CAGCATGGGCTCCAGTAG
hPXR10R	exon 9a	CCTGTGATGCCGAACAAC
hPXR11F	exon 9	CATTGAATGCAATCGGCC
hPXR12R	exon 9a	GCTCTTGGCAGTGTCCAT
hPXR15F	exon 2	GGAAAGCCCAGTGTCAAC
hPXR16F	exon 3	CCATGAAACGCAACGCCC
hPXR18R	exon 2	CCTTGCATCCTTCACATG
hPXR19R	exon 3	CATGCCGCTCTCCAGGCA
hPXR20R	exon 4	CGGCCTCGTCGGACATGA
hPXR21R	exon 5/6	ACATGTCAGCCATGTGGG
hPXR47F	exon 1b	CAAGCCAAGTGTTCACAGTG
hPXR48R	exon 1b	CACTGTGAACACTTGGCTTG
hPXR52F	exon 1a	CAAGGACAGCAGCATGACAGTCAC
hPXR54R	exon 1a	AGCCAACTCAGCCGCAGC

[0089] Fifty ng of genomic DNA was added to a reaction mix (total volume 30 or 50 μ l) containing 1x PCR buffer (Q=Qiagen, Cat.Nr. 1005479, or B2=Boehringer (currently Roche) Expand Long Template PCR Buffer number 2, Cat. Nr. 1742655), 0.25 μ M each oligonucleotide (Metabion), 200 μ M dNTPs, and 1 U of Taq polymerase (Qiagen). Amplifications were performed on a RoboCycler Gradient 96 (Stratagene) with an initial denaturation step of 2 min. at 94 °C followed by 32 amplification cycles of denaturation (40 sec., 94 °C), annealing (45 sec., temperatures 56-60 °C), and extension (60-150 sec., 72 °C). This was followed by a final extension step 5 min., 72 °C All sequencing reactions were performed on a GeneAmp PCR System 9700 (Perkin-Elmer) using a dye-terminator DNA sequencing kit (Perkin-Elmer, Cat.Nr. 4303154), according to manufacturers's instructions

Table 4.

Exon-intron organization of the hPXR gene.				
Exon number	Exon size (b)	Sequence at exon-intron junction		Intron size (kb)
		5' splice site	3' splice site	
1b	281	AAGCAG gtatgg....	-	0.403
1a	144	AAACCA gtgagt....ttctag TCCAAG	7.0
2	219	TTTCAG gtagag....tcacag GAGGGC	~ 2.7

Table 4. (continued)

Exon-intron organization of the hPXR gene.				
Exon number	Exon size (b)	Sequence at exon-intron junction		Intron size (kb)
3	134	AGGAGA gtgagc.... ctgcag TGATCA	~ 1.2
4	188	TTCCGG gtagga....tcctag CTGCCA	~ 1.0
5/6	275	CTTCAG gtagga....tgccag GGACTT	~ 1.9
7	143	CTGCAG gtgccc....ccacag GTGGCT	0.201
8	117	CCCCAG gtgagg....ctccag ACCGCC	0.286
9	106	TCATAG gtgagc....atgcag GTTCTT	~ 1.3
9a	1418			

[0090] The sizes of exons 1b and 1a based on a comparison of genomic (Figure 8), and cDNA (GenBank accession numbers AF061056.1, AF084645 AF084644), hPXR sequences.

Table 5. hPXR polymorphism screen: oligonucleotide sequences, amplification conditions and fragment size.

Exon	Upstream Oligonucleotide		Downstream Oligonucleotide		Ann. Temp. (°C)	Buffer	Product Size (bp)
	Name	Sequence (5'-3')	Name	Sequence (5'-3')			
1b	HPXR57F	TCAAGTGTGGACTTGGGAC	HPXR58R	CCCACTATGATGCTGACCTC	53	B2	460
1a							
2	HPXR41F	CTGAGGCCCTCTACACATC	HPXR40R	AGGCCCTGAGATGTTACC	55	Q	345
3							
4							
5/6	HPXR32F	CTGAGTTGGGACCTGTCT	HPXR35R	CCAGGCCCTTTGAACCTC	60	B2	415
7&8	HPXR36F	CTGCTGGTGCCGGCCTGT	HPXR33R	GACTGGGACCTTCCCTGG	60	B2	598
9	HPXR34F	GAGCAATGCCCTGACTCT	HPXR26R	CCCTCTGGCCATGAAGTC	60	B2	271
9a	HPXR30F	TGCTTGTGCAGCCTCAGA	HPXR12R	GCTCTGGCAGTGTCAT	60	B2	324

Preliminary exon numbering. Fifty ng of genomic DNA was added to a reaction mix (total volume 30 or 50 µl) containing 1x PCR buffer (Q=Qiagen, Cat.Nr. 1005479, or B2=Boehringer (currently Roche) Expand Long Template PCR Buffer number 2, Cat. Nr. 1742655), 0.25 µM each oligonucleotide (Metabion), 200 µM dNTPs, and 1 U of Taq polymerase (Qiagen). Amplifications were performed on a RoboCycler Gradient 96 (Stratagene) with an initial denaturation step of 2 min. at 94 °C followed by 32 amplification cycles of denaturation (40 sec., 94 °C), annealing (45 sec., temperatures given above), and extension (60 sec., 72 °C). This was followed by a final extension step 5 min., 72 °C All sequencing reactions were performed on a GeneAmp PCR System 9700 (Perkin-Elmer) using a dye-terminator DNA sequencing kit (Perkin-Elmer, Cat.Nr. 4303154), according to manufacturers's instructions.

Table 6.

Distribution of polymorphisms in CYP3A4 (exons 3, 4, 5, 7 and 9) and CYP3A7 (exon 11, in **bold**) in a set of 22 DNA samples.

Number	Donor Number	Exons												
		1	2	3	4	5	6	7	8	9	10	11	12	13
1	11			-	-	-		-		-		-		
2	17			-	-	-		-		-		-		
3	18			-	-	-		-		-		X		
4	19			-	-	-		-		-		-		
5	20			-	-	-		-		-		-		
6	21			-	-	-		-		-		-		
7	22			-	-	-		-		-		-		
8	23			-	-	-		-		-		-		
9	24			-	-	-		X		-		X		
10	25			-	-	-		-		-		X		
11	27			-	-	-		-		-		-		
12	29			-	-	-		-		-		-		
13	31			-	-	-		-		-		-		
14	33			-	-	-		-		-		-		
15	34			-	-	-		-		-		-		
16	35			-	-	-		-		-		X		
17	36			-	-	-		-		-		-		
18	37			-	-	-		-		-		-		
19	38			-	-	-		X		-		-		
20	40			X	-	-		-		-		-		
21	41			-	-	-		X		-		X		
22	43			-	-	-		X		-		X		

"-"=wild-type, "X"=heterozygote, "XX"=homozygote

Table 7.

Distribution of hPXR gene polymorphisms in a set of 22 DNA samples.

Number	Donor Number	Exons									
		1b	1a	2	3	4	5/6	7	8	9	9a
1	11			-			-	X	-	-	-
2	17	X		-			-	-	-	-	-
3	18	XX		-			-	-	-	-	-
4	19	X		-			-	-	-	-	-
5	20	X		-			-	-	-	-	-
6	21	XX		-			-	X	-	-	-

Table 7. (continued)

Distribution of hPXR gene polymorphisms in a set of 22 DNA samples.											
Number	Donor	Exons									
	Number	1b	1a	2	3	4	5/6	7	8	9	9a
7	22	XX		-			-	-	-	-	-
8	23	XX		-			-	-	-	-	-
9	24	XX		-			-	-	-	-	-
10	25	X		-			-	-	--	-	-
11	27	-		-			XX	XX	-	-	-
12	29	XX		-			-	X	-	-	-
13	31	X		-			-	X	-	-	-
14	33	-		-			-	-	-	-	-
15	34	X		-			-	-	-	-	-
16	35	XX		-			-	-	-	-	-
17	36	X		-			-	-	-	-	-
18	37	X		-			-	-	-	-	-
19	38	-		-			-	X	-	-	-
20	40	XX		-			-	X	-	-	-
21	41	X		-			-	-	-	-	-
22	43	XX		-			-	-	-	-	-
"-="wild-type, "X"=heterozygote, "XX"=homozygote											

Table 8. Genetic variants of CYP3A4, CYP3A7 and hPXR.

Gene	Position	wt sequence (5'-3')	mut sequence (5'-3')
CYP3A4	exon 3	F: TCCCAGGGCTTTTGT	F: TCCCAGGACTTTTGT
		R: ACAAAGCCCTGGGA	R: ACAAAGTCCTGGGA
	intron 7	F: TATCTTTCTCTCTT	F: TATCTTGCTCTCTT
		R: AAGAGAGAAAGATA	R: AAGAGAGCAAGATA
CYP3A7	exon 11	F: TACTGGACAGAGC	F: TACTGGAGAGAGC
		R: GCTCTGTCCAGTA	R: GCTCTCTCCAGTA
hPXR	exon 1b	F: CCTGAA C AAGGCAG	F: CCTGAA A AAGGCAG
		R: CTGCCTTGTTTCAGG	R: CTGCCTTTTTTCAGG
	exon 5/6	F: CAGTGGCGGGAAA	F: CAGTGGTGGGAAA
		R: TTTCCCGCCACTG	R: TTTCCCACCACTG
	intron 7	F: CCTCCAT C CTGTTAC	F: CCTCCAT T CTGTTAC
		R: GTAACAG G ATGGAGG	R: GTAACAG A ATGGAGG

References

[0091]

- (1) Daly, Toxicol Lett 102-103 (1998), 143-7
- (2) Touw, Drug Metabol Drug Interact 14 (1997), 55-82
- (3) Thummel, Annu Rev Pharmacol Toxicol 38 (1998), 389-430
- (4) Cholerton, Trends Pharmacol Sci 13 (1992), 434-9
- (5) Ketter, J Clin Psychopharmacol 15 (1995), 387-98
- (6) Forrester, Proc Natl Acad Sci U S A 87 (1990), 8306-10
- (7) Paolini, Nature 398 (1999), 760-1
- (8) Westlind, Biochem Biophys Res Commun 259 (1999), 201-5
- (9) Jounaidi, Biochem Biophys Res Commun 221 (1996), 466-70
- (10) Schuetz, Pharmacogenetics 4 (1994), 11-20
- (11) Hunt, Clin Pharmacol Ther 51 (1992), 18-23
- (12) Kashuba, Clin Pharmacol Ther 64 (1998), 269-77
- (13) Peyronneau, Eur J Biochem 218 (1993), 355-61
- (14) Rebbeck, J Natl Cancer Inst 90 (1998), 1225-9
- (15) Felix, Proc Natl Acad Sci U S A 95 (1998), 13176-81
- (16) He, Biochemistry 36 (1997), 8831-9
- (17) Szklarz, J Comput Aided Mol Des 11 (1997), 265-72
- (18) Harlow, J Biol Chem 272 (1997), 5396-402
- (19) Wang, Biochemistry 37 (1998), 12536-45

- (20) Harlow, Proc Natl Acad Sci U S A 95 (1998), 6636-41
(21) Domanski, Arch Biochem Biophys 350 (1998), 223-32
(22) Lehmann, J Clin Invest 102 (1998), 1016-23
(23) Bertilsson, Proc Natl Acad Sci U S A 95 (1998), 12208-13
5 (24) Kliewer, Cell 92 (1998), 73-82
(25) Pascussi, Biochem Biophys Res Commun 260 (1999), 377-81

10

15

20

25

30

35

40

45

50

55

SEQUENCE LISTING

5 <110> EPIDAUROS Biotechnologie Aktiengesellschaft

<120> Polymorphisms in the human CYP3A4, CYP3A7 and hPXR
genes and their use in diagnostic and therapeutic
applications

10 <130> D2145EP

<140>

<141>

15 <160> 135

<170> PatentIn Ver. 2.1

<210> 1

20 <211> 20

<212> DNA

<213> Artificial Sequence

<220>

25 <223> Description of Artificial Sequence: DNA

<400> 1

taatacgact cactataggg 20

30 <210> 2

<211> 18

<212> DNA

<213> Artificial Sequence

35 <220>

<223> Description of Artificial Sequence: DNA

<400> 2

gaaccattc acatggac 18

40 <210> 3

<211> 18

<212> DNA

45 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: DNA

<400> 3

50 tgatcatgtc aggatctg 18

<210> 4

55

<211> 18
<212> DNA
<213> Artificial Sequence

5

<220>
<223> Description of Artificial Sequence: DNA

<400> 4
ggccaacagc ctgtgctg

10

18

<210> 5
<211> 18
<212> DNA
<213> Artificial Sequence

15

<220>
<223> Description of Artificial Sequence: DNA

<400> 5
tccactggtg aaggttgg

20

18

<210> 6
<211> 18
<212> DNA
<213> Artificial Sequence

25

<220>
<223> Description of Artificial Sequence: DNA

30

<400> 6
gtgccatctc tatagctg

18

<210> 7
<211> 18
<212> DNA
<213> Artificial Sequence

35

<220>
<223> Description of Artificial Sequence: DNA

40

<400> 7
cttccccgct cagatttc

45

18

<210> 8
<211> 18
<212> DNA
<213> Artificial Sequence

50

<220>
<223> Description of Artificial Sequence: DNA

55

5

10

15

15

20

25

25

30

35

40

45

50

55

5 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 10 <400> 13
 cctttgtggg actcagtttc 20

 <210> 14
 <211> 18
 15 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 20 <400> 14
 gccactcacc ctgatgtc 18

 <210> 15
 25 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <220>
 30 <223> Description of Artificial Sequence: DNA

 <400> 15
 atcaccaccc accctttg 18

 35 <210> 16
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 40 <220>
 <223> Description of Artificial Sequence: DNA

 <400> 16
 45 caaagggtgg gtggtgat 18

 <210> 17
 <211> 18
 <212> DNA
 50 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 55

5 <211> 24
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 <400> 22
 10 cttacgcttc tgccagtagc aacc 24

 <210> 23
 <211> 20
 <212> DNA
 15 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 <400> 23
 20 aacaggcgtg gaaacacaat 20

 <210> 24
 25 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <220>
 30 <223> Description of Artificial Sequence: DNA

 <400> 24
 ctttcctgcc ctgcacag 18

 35 <210> 25
 <211> 22
 <212> DNA
 <213> Artificial Sequence

 40 <220>
 <223> Description of Artificial Sequence: DNA

 <400> 25
 45 cctctaactg ccagcaagtc tg 22

 <210> 26
 <211> 21
 <212> DNA
 50 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 55

5 <400> 26
gcgctgagac tgtcctctgt g 21

<210> 27
<211> 24
<212> DNA
10 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNA

15 <400> 27
agtctggctt cctgggttgg gctc 24

<210> 28
<211> 26
20 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNA

25 <400> 28
gaagtggacg tggaaccttc ctggac 26

30 <210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

35 <220>
<223> Description of Artificial Sequence: DNA

<400> 29
ctacaacctat ggagacctcc 20

40 <210> 30
<211> 20
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Description of Artificial Sequence: DNA

50 <400> 30
tacctgtccc caccagattc 20

<210> 31

55

5 <211> 23
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 10 <400> 31
 gtctgtcttg actggacatg tgg 23

 15 <210> 32
 <211> 22
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 20 <400> 32
 gatgatggtc acacatatct tc 22

 25 <210> 33
 <211> 23
 <212> DNA
 <213> Artificial Sequence

 30 <220>
 <223> Description of Artificial Sequence: DNA

 <400> 33
 ggagatcaag gaccacgctt gtg 23

 35 <210> 34
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 40 <220>
 <223> Description of Artificial Sequence: DNA

 <400> 34
 ctcacatcc tggaatactt cctgc 25

 45

 50 <210> 35
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 55

	<400> 35	
	ccagtatgag ttgttctctg g	21
5		
	<210> 36	
	<211> 24	
	<212> DNA	
10	<213> Artificial Sequence	
	<220>	
	<223> Description of Artificial Sequence: DNA	
	<400> 36	
15	aggcagaata tgcttgaacc aggc	24
	<210> 37	
	<211> 18	
20	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Description of Artificial Sequence: DNA	
25	<400> 37	
	tcatgtccga cgaggccg	18
	<210> 38	
30	<211> 18	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	
35	<223> Description of Artificial Sequence: DNA	
	<400> 38	
	cccacatggc tgacatgt	18
40		
	<210> 39	
	<211> 18	
	<212> DNA	
	<213> Artificial Sequence	
45		
	<220>	
	<223> Description of Artificial Sequence: DNA	
	<400> 39	
50	cccatcgagg accagatc	18
	<210> 40	
55		

5 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 10 <400> 40
 gtcttccaag cagtagga 18

 <210> 41
 <211> 18
 <212> DNA
 15 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 20 <400> 41
 cagcatgggc tccagtag 18

 <210> 42
 25 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <220>
 30 <223> Description of Artificial Sequence: DNA

 <400> 42
 cctgtgatgc cgaacaac 18

 35 <210> 43
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 40 <220>
 <223> Description of Artificial Sequence: DNA

 <400> 43
 45 cattgaatgc aatcggcc 18

 <210> 44
 <211> 18
 <212> DNA
 50 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 55

	<400> 44	
	gctcctggca gtgtccat	18
5		
	<210> 45	
	<211> 18	
	<212> DNA	
10	<213> Artificial Sequence	
	<220>	
	<223> Description of Artificial Sequence: DNA	
	<400> 45	
15	ggaaagccca gtgtcaac	18
	<210> 46	
	<211> 18	
20	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Description of Artificial Sequence: DNA	
25		
	<400> 46	
	ccatgaaacg caacgccc	18
	<210> 47	
30	<211> 18	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	
35	<223> Description of Artificial Sequence: DNA	
	<400> 47	
	ccttgcatcc ttcacatg	18
40		
	<210> 48	
	<211> 18	
	<212> DNA	
45	<213> Artificial Sequence	
	<220>	
	<223> Description of Artificial Sequence: DNA	
	<400> 48	
50	catgccgctc tccaggca	18
	<210> 49	
55		

5 <211> 18
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: DNA
 <400> 49
 10 cggcctcgtc ggacatga 18
 <210> 50
 <211> 18
 <212> DNA
 15 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: DNA
 20 <400> 50
 acatgtcagc catgtggg 18
 <210> 51
 25 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <220>
 30 <223> Description of Artificial Sequence: DNA
 <400> 51
 caagccaagt gttcacagtg 20
 35 <210> 52
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 40 <220>
 <223> Description of Artificial Sequence: DNA
 <400> 52
 45 cactgtgaac acttggcttg 20
 <210> 53
 <211> 24
 <212> DNA
 50 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: DNA
 55

5 <400> 53
caaggacagc agcatgacag tcac 24

<210> 54
<211> 20
<212> DNA
10 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNA

15 <400> 54
agcccaactca gccgcagc 18

<210> 55
<211> 12
20 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNA

25 <400> 55
aagcaggtat gg 12

30 <210> 56
<211> 12
<212> DNA
<213> Artificial Sequence

35 <220>
<223> Description of Artificial Sequence: DNA

<400> 56
aaaccagtga gt 12

40 <210> 57
<211> 12
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Description of Artificial Sequence: DNA

50 <400> 57
ttctagtcca ag 12

<210> 58

55

5 <211> 12
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 <400> 58
 10 tttcaggtag ag 12

 <210> 59
 <211> 12
 <212> DNA
 15 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 <400> 59
 20 tcacaggagg gc 12

 <210> 60
 25 <211> 12
 <212> DNA
 <213> Artificial Sequence

 <220>
 30 <223> Description of Artificial Sequence: DNA

 <400> 60
 aggagagtga gc 12

 35 <210> 61
 <211> 12
 <212> DNA
 <213> Artificial Sequence

 40 <220>
 <223> Description of Artificial Sequence: DNA

 <400> 61
 45 ctgcagtgat ca 12

 <210> 62
 <211> 12
 <212> DNA
 50 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 55

	<400> 62	
5	ttccgggtag ga	12
	<210> 63	
	<211> 12	
	<212> DNA	
10	<213> Artificial Sequence	
	<220>	
	<223> Description of Artificial Sequence: DNA	
	<400> 63	
15	tcctagctgc ca	12
	<210> 64	
	<211> 12	
20	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Description of Artificial Sequence: DNA	
25	<400> 64	
	cttcaggtag ga	12
30	<210> 65	
	<211> 12	
	<212> DNA	
	<213> Artificial Sequence	
35	<220>	
	<223> Description of Artificial Sequence: DNA	
	<400> 65	
40	tgccagggac tt	12
	<210> 66	
	<211> 12	
	<212> DNA	
45	<213> Artificial Sequence	
	<220>	
	<223> Description of Artificial Sequence: DNA	
	<400> 66	
50	ctgcaggtgc cc	12
	<210> 67	
55		

5 <211> 12
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 10 <400> 67
 ccacaggtgg ct 12

 <210> 68
 <211> 12
 <212> DNA
 15 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 20 <400> 68
 ccccaggtga gg 12

 <210> 69
 25 <211> 12
 <212> DNA
 <213> Artificial Sequence

 <220>
 30 <223> Description of Artificial Sequence: DNA

 <400> 69
 ctccagaccg cc 12

 35 <210> 70
 <211> 12
 <212> DNA
 <213> Artificial Sequence

 40 <220>
 <223> Description of Artificial Sequence: DNA

 <400> 70
 45 tcataggtga gc 12

 <210> 71
 <211> 12
 <212> DNA
 50 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 55

```
<400> 71
atgcagggttc tt
```

12

```
<210> 72
<211> 20
<212> DNA
<213> Artificial Sequence
```

<220>
<223> Description of Artificial Sequence: DNA

```
<400> 72
tcaagtgctg gacttgggac
```

20

```
<210> 73
<211> 20
<212> DNA
<213> Artificial Sequence
```

<220>
<223> Description of Artificial Sequence: DNA

<400> 73
cccactatga tgctgacctc

20

```
<210> 74
<211> 18
<212> DNA
<213> Artificial Sequence
```

<220>
<223> Description of Artificial Sequence: DNA

<400> 74
ctgaggcctc tacacatc

18

```
<210> 75
<211> 18
<212> DNA
<213> Artificial Sequence
```

<220>
<223> Description of Artificial Sequence: DNA

<400> 75
aggccctgag atgttacc

18

<210> 76

5 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 <400> 76
 10 ctgagttggg acctgtct 18

 <210> 77
 <211> 18
 <212> DNA
 15 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 <400> 77
 20 ccaggccctt tgaacctc 18

 <210> 78
 25 <211> 18
 <212> DNA
 <213> Artificial Sequence

 <220>
 30 <223> Description of Artificial Sequence: DNA

 <400> 78
 ctgctggtgc cggcctgt 18

 35 <210> 79
 <211> 18
 <212> DNA
 <213> Artificial Sequence

 40 <220>
 <223> Description of Artificial Sequence: DNA

 <400> 79
 45 gactgggacc ttccctgg 18

 <210> 80
 <211> 18
 <212> DNA
 50 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 55

5 <400> 80
gagcaatgcc ctgactct 18

<210> 81
<211> 18
<212> DNA
10 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNA

15 <400> 81
ccctctggcc atgaagtc 18

<210> 82
<211> 18
20 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNA

25 <400> 82
tgcttgtgca gcctcaga 18

30 <210> 83
<211> 18
<212> DNA
<213> Artificial Sequence

35 <220>
<223> Description of Artificial Sequence: DNA

<400> 83
gctcttggca gtgtccat 18

40 <210> 84
<211> 15
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Description of Artificial Sequence: DNA

50 <400> 84
tcccagggct tttgt 15

<210> 85

55

5
 <211> 15
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: DNA

10
 <400> 85
 acaaaaagccc tggga 15

<210> 86
 <211> 15
 <212> DNA
 <213> Artificial Sequence

15
 <220>
 <223> Description of Artificial Sequence: DNA

20
 <400> 86
 tcccaggact tttgt 15

<210> 87
 <211> 15
 <212> DNA
 <213> Artificial Sequence

25
 <220>
 <223> Description of Artificial Sequence: DNA

30
 <400> 87
 acaaaaagtcc tggga 15

35
 <210> 88
 <211> 14
 <212> DNA
 <213> Artificial Sequence

40
 <220>
 <223> Description of Artificial Sequence: DNA

45
 <400> 88
 tatctttctc tctt 14

<210> 89
 <211> 14
 <212> DNA
 <213> Artificial Sequence

50
 <220>
 <223> Description of Artificial Sequence: DNA

55

	<400> 89	
	aagagagaaa gat	13
5		
	<210> 90	
	<211> 14	
	<212> DNA	
10	<213> Artificial Sequence	
	<220>	
	<223> Description of Artificial Sequence: DNA	
	<400> 90	
15	tatcttgctc tctt	14
	<210> 91	
	<211> 14	
20	<212> DNA	
	<213> Artificial Sequence	
	<220>	
	<223> Description of Artificial Sequence: DNA	
25	<400> 91	
	aagagagcaa gata	14
	<210> 92	
30	<211> 13	
	<212> DNA	
	<213> Artificial Sequence	
	<220>	
35	<223> Description of Artificial Sequence: DNA	
	<400> 92	
	tactggacag agc	13
40		
	<210> 93	
	<211> 13	
	<212> DNA	
	<213> Artificial Sequence	
45	<220>	
	<223> Description of Artificial Sequence: DNA	
	<400> 93	
50	gctctgtcca gta	13
	<210> 94	
55		

5 <211> 13
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 10 <400> 94
 tactggagag agc 13

 <210> 95
 <211> 13
 <212> DNA
 15 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 20 <400> 95
 gctctctcca gta 13

 <210> 96
 25 <211> 14
 <212> DNA
 <213> Artificial Sequence

 <220>
 30 <223> Description of Artificial Sequence: DNA

 <400> 96
 cctgaacaag gcag 14

 35 <210> 97
 <211> 14
 <212> DNA
 <213> Artificial Sequence

 40 <220>
 <223> Description of Artificial Sequence: DNA

 <400> 97
 45 ctgccttggt cagg 14

 <210> 98
 <211> 14
 <212> DNA
 50 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: DNA

 55

5 <400> 98
cctgaaaaag gcag 14

<210> 99
<211> 14
<212> DNA
10 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNA

15 <400> 99
ctgccttttt cagg 14

<210> 100
<211> 13
20 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: DNA

25 <400> 100
cagtggcggg aaa 13

30 <210> 101
<211> 13
<212> DNA
<213> Artificial Sequence

35 <220>
<223> Description of Artificial Sequence: DNA

<400> 101
tttcccgcca ctg 13

40 <210> 102
<211> 13
<212> DNA
<213> Artificial Sequence

45 <220>
<223> Description of Artificial Sequence: DNA

50 <400> 102
cagtgggtggg aaa 13

<210> 103

55

5
 <211> 13
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: DNA

10
 <400> 103
 tttcccacca ctg 13

<210> 104
 <211> 15
 <212> DNA
 <213> Artificial Sequence

15
 <220>
 <223> Description of Artificial Sequence: DNA

20
 <400> 104
 cctccatcct gttac 15

<210> 105
 <211> 15
 <212> DNA
 <213> Artificial Sequence

25
 <220>
 <223> Description of Artificial Sequence: DNA

30
 <400> 105
 gtaacaggat ggagg 15

35
 <210> 106
 <211> 15
 <212> DNA
 <213> Artificial Sequence

40
 <220>
 <223> Description of Artificial Sequence: DNA

45
 <400> 106
 cctccattct gttac 15

<210> 107
 <211> 15
 <212> DNA
 <213> Artificial Sequence

50
 <220>
 <223> Description of Artificial Sequence: DNA

55

EP 1 088 900 A1

5 <400> 107
gtaacagaat ggagg 15

<210> 108
<211> 249
<212> DNA
10 <213> Homo sapiens

<220>
<221> intron
<222> (1)..(115)

15 <220>
<221> exon
<222> (116)..(168)

20 <220>
<221> intron
<222> (169)..(249)

25 <220>
<221> CDS
<222> (116)..(166)

<400> 108
cctctaactg ccagcaagtc tgatttcatt ggcttcgact gttttcatcc caattagagg 60

30 caggggtaag tacattaataa ataataatca aatattatgt tgtttctcct cccag grc 118
Xaa
1

35 ttt tgt atg ttt gac atg gaa tgt cat aaa aag tat gga aaa gtg tgg 166
Phe Cys Met Phe Asp Met Glu Cys His Lys Lys Tyr Gly Lys Val Trp
5 10 15

gggtgagtat tctggaaaact tccattggat agacttggtt ctatgatgag tttaccccac 226

40 tgcacagagg acagtctcag ccc 249

<210> 109
<211> 17
<212> PRT
45 <213> Homo sapiens

<400> 109
Xaa Phe Cys Met Phe Asp Met Glu Cys His Lys Lys Tyr Gly Lys Val
1 5 10 15

50 Trp

55

EP 1 088 900 A1

5 <210> 110
 <211> 293
 <212> DNA
 <213> Homo sapiens

10 <220>
 <221> intron
 <222> (1)..(77)

15 <220>
 <221> exon
 <222> (78)..(177)

20 <220>
 <221> intron
 <222> (178)..(293)

25 <400> 110
 agtctggcctt cctggggttg gctccagctg tagaataagg ctgttgatgt ttaatcaact 60

30 cgtgttttttt cacacagc ttt tat gat ggt caa cag cct gtg ctg gct atc 111
 Phe Tyr Asp Gly Gln Gln Pro Val Leu Ala Ile
 1 5 10

35 aca gat cct gac atg atc aaa aca gtg cta gtg aaa gaa tgt tat tct 159
 Thr Asp Pro Asp Met Ile Lys Thr Val Leu Val Lys Glu Cys Tyr Ser
 15 20 25

40 gtc ttc aca aac cgg agg gtaagcattc atgtgttgaa attaaaatac 207
 Val Phe Thr Asn Arg Arg
 30

45 tgattgatta aatttatatt ttgaaattct tatatatcca tagacagtg cctaaaaaat 267

50 gtccaggaag gttccacgtc cacttc 293

55 <210> 111
 <211> 33
 <212> PRT
 <213> Homo sapiens

60 <400> 111
 Phe Tyr Asp Gly Gln Gln Pro Val Leu Ala Ile Thr Asp Pro Asp Met
 1 5 10 15

Ile Lys Thr Val Leu Val Lys Glu Cys Tyr Ser Val Phe Thr Asn Arg
 20 25 30

Arg

5

<210> 112
 <211> 236
 <212> DNA
 <213> Homo sapiens

10

<220>
 <221> intron
 <222> (1)..(61)

15

<220>
 <221> exon
 <222> (62)..(175)

20

<220>
 <221> intron
 <222> (176)..(236)

25

<220>
 <221> CDS
 <222> (62)..(175)

<400> 112
 ctacaacccat ggagacctcc acaactgatg taggacaaaa tgtttctgct ttgaactcta 60

30

g cct ttt ggt cca gtg gga ttt atg aaa agt gcc atc tct ata gct gag 109
 Pro Phe Gly Pro Val Gly Phe Met Lys Ser Ala Ile Ser Ile Ala Glu
 1 5 10 15

35

gat gaa gaa tgg aag aga tta cga tca ttg ctg tct cca acc ttc acc 157
 Asp Glu Glu Trp Lys Arg Leu Arg Ser Leu Leu Ser Pro Thr Phe Thr
 20 25 30

agt gga aaa ctc aag gag gtatgaaaat aacatgagtt ttaataagaa 205
 Ser Gly Lys Leu Lys Glu
 35

40

acttaaagaa tgaatctggt ggggacaggt a 236

45

<210> 113
 <211> 38
 <212> PRT
 <213> Homo sapiens

50

<400> 113
 Pro Phe Gly Pro Val Gly Phe Met Lys Ser Ala Ile Ser Ile Ala Glu
 1 5 10 15

55

EP 1 088 900 A1

Asp Glu Glu Trp Lys Arg Leu Arg Ser Leu Leu Ser Pro Thr Phe Thr
20 25 30

5 Ser Gly Lys Leu Lys Glu
35

10 <210> 114
<211> 393
<212> DNA
<213> Homo sapiens

15 <220>
<221> intron
<222> (1)..(98)

<220>
<221> exon
20 <222> (99)..(247)

<220>
<221> intron
<222> (248)..(393)

25 <220>
<221> CDS
<222> (100)..(246)

30 <400> 114
gtctgtcttg actggacatg tggctttcct gatgcacgca tagaggaagg atggtaaaaa 60

ggtgctgatt ttaattttcc acatctttct ccactcagc gtc ttt ggg gcc tac 114
Val Phe Gly Ala Tyr
1 5

35 agc atg gat gtg atc act agc aca tca ttt gga gtg aac atc gac tct 162
Ser Met Asp Val Ile Thr Ser Thr Ser Phe Gly Val Asn Ile Asp Ser
10 15 20

40 ctc aac aat cca caa gac ccc ttt gtg gaa aac acc aag aag ctt tta 210
Leu Asn Asn Pro Gln Asp Pro Phe Val Glu Asn Thr Lys Lys Leu Leu
25 30 35

45 aga ttt gat ttt ttg gat cca ttc ttt ctc tca ata agtatgtgga 256
Arg Phe Asp Phe Leu Asp Pro Phe Phe Leu Ser Ile
40 45

ctactatttc cttttattta tcttctctc ttaaaaataa ctgctttatt gagatataaa 316

50 tcaccatgta attcatccac ttaaaatata cagttcagtg atttgtagta catttgaaga 376

tatgtgtgac catcatc 393

55

EP 1 088 900 A1

5 <210> 115
 <211> 49
 <212> PRT
 <213> Homo sapiens

 <400> 115
 Val Phe Gly Ala Tyr Ser Met Asp Val Ile Thr Ser Thr Ser Phe Gly
 1 5 10 15
 Val Asn Ile Asp Ser Leu Asn Asn Pro Gln Asp Pro Phe Val Glu Asn
 20 25 30
 15 Thr Lys Lys Leu Leu Arg Phe Asp Phe Leu Asp Pro Phe Phe Leu Ser
 35 40 45
 Ile

 20
 <210> 116
 <211> 240
 <212> DNA
 25 <213> Homo sapiens

 <220>
 <221> intron
 <222> (1)..(82)
 30
 <220>
 <221> exon
 <222> (83)..(149)
 35
 <220>
 <221> intron
 <222> (150)..(240)
 40
 <220>
 <221> CDS
 <222> (83)..(148)

 <400> 116
 ggagatcaag gaccacgctt gtgatttact tctgacttca ggagccactt tctgtcagtg 60
 45 aaattttctct ttttgcttct ag cac cga gtg gat ttc ctt cag ctg atg att 112
 His Arg Val Asp Phe Leu Gln Leu Met Ile
 1 5 10
 gac tct cag aat tca aaa gaa act gag tcc cac aaa ggtaaccaga 158
 50 Asp Ser Gln Asn Ser Lys Glu Thr Glu Ser His Lys
 15 20
 gtgtttctga gggctacttg tggggcactc agagggaagg ccttggtctg aaaatgtgca 218
 55

240

```
<210> 117
<211> 22
<212> PRT
<213> Homo sapiens
```

<400> 117
His Arg Val Asp Phe Leu Gln Leu Met Ile Asp Ser Gln Asn Ser Lys
1 5 10 15

Glu Thr Glu Ser His Lys
20

```
<210> 118
<211> 399
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> intron
<222> (1)..(111)
```

```
<220>
<221> exon
<222> (112) .. (338)
```

```
<220>
<221> intron
<222> (339)..(399)
```

```

<400> 118
ccagtatgag ttgttctctg gaacttctaa cagttcaaca gtactacatg gactgagtta 60
aaagttaatt caaaaatctc aatttatcca aatctgtttc tttcttttca g gca cca 117
                                     Ala Pro
                                     1

```

ccc acc tat gat act gtg cta cag ttg gag tat ctt gac atg gtg gtg 165
Pro Thr Tyr Asp Thr Val Leu Gln Leu Glu Tyr Leu Asp Met Val Val
5 10 15

aat gaa aca ctc aga tta ttc cca gtt gct atg aga ctt gag agg gtc 213
Asn Glu Thr Leu Arg Leu Phe Pro Val Ala Met Arg Leu Glu Arg Val
20 25 30



EP 1 088 900 A1

tgc aaa aaa gat gtt gaa atc aat ggg atg ttt att ccc aaa ggg gtg 261
 Cys Lys Lys Asp Val Glu Ile Asn Gly Met Phe Ile Pro Lys Gly Val
 35 40 45 50
 5
 gtg gtg atg att cca agc tat gtt ctt cat cat gac cca aag tac tgg 309
 Val Val Met Ile Pro Ser Tyr Val Leu His His Asp Pro Lys Tyr Trp
 55 60 65
 10
 asa gag cct gag aag ttc ctc cct gaa aggtaggagg cccctgggaa 356
 Xaa Glu Pro Glu Lys Phe Leu Pro Glu
 70 75
 gggagccctc cctgaaccag cctgggttcaa gcatattctg cct 399
 15
 <210> 119
 <211> 75
 <212> PRT
 <213> Homo sapiens
 20
 <400> 119
 Ala Pro Pro Thr Tyr Asp Thr Val Leu Gln Leu Glu Tyr Leu Asp Met
 1 5 10 15
 25
 Val Val Asn Glu Thr Leu Arg Leu Phe Pro Val Ala Met Arg Leu Glu
 20 25 30
 Arg Val Cys Lys Lys Asp Val Glu Ile Asn Gly Met Phe Ile Pro Lys
 35 40 45
 30
 Gly Val Val Val Met Ile Pro Ser Tyr Val Leu His His Asp Pro Lys
 50 55 60
 Tyr Trp Xaa Glu Pro Glu Lys Phe Leu Pro Glu
 65 70 75
 35
 <210> 120
 <211> 962
 40
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> intron
 45
 <222> (1)..(66)
 <220>
 <221> intron
 <222> (348)..(750)
 50
 <220>
 <221> exon
 <222> (751)..(894)

EP 1 088 900 A1

<213> Homo sapiens

<400> 121

5 Met Thr Val Thr Arg Thr His His Phe Lys Glu Gly Ser Leu Arg Ala
1 5 10 15

Pro Ala Ile Pro Leu His Ser Ala Ala Ala Glu Leu Ala Ser Asn
20 25 30

10

<210> 122

<211> 345

<212> DNA

15

<213> Homo sapiens

<220>

<221> intron

<222> (1)..(60)

20

<220>

<221> exon

<222> (61)..(279)

25

<220>

<221> intron

<222> (280)..(345)

<220>

<221> CDS

<222> (62)..(277)

30

<400> 122

ctgaggcctc tacacatccc tgtccagtct ttccattctc tgtgggtttc tcatttctag 60

35

t cca aga ggc cca gaa gca aac ctg gag gtg aga ccc aaa gaa agc tgg 109

Pro Arg Gly Pro Glu Ala Asn Leu Glu Val Arg Pro Lys Glu Ser Trp
1 5 10 15

aac cat gct gac ttt gta cac tgt gag gac aca gag tct gtt cct gga 157

40

Asn His Ala Asp Phe Val His Cys Glu Asp Thr Glu Ser Val Pro Gly
20 25 30

aag ccc agt gtc aac gca gat gag gaa gtc gga ggt ccc caa atc tgc 205

45

Lys Pro Ser Val Asn Ala Asp Glu Glu Val Gly Gly Pro Gln Ile Cys
35 40 45

cgt gta tgt ggg gac aag gcc act ggc tat cac ttc aat gtc atg aca 253

Arg Val Cys Gly Asp Lys Ala Thr Gly Tyr His Phe Asn Val Met Thr
50 55 60

50

tgt gaa gga tgc aag ggc ttt ttc aggtagagtt acccatcagc cttcacccac 307

Cys Glu Gly Cys Lys Gly Phe Phe
65 70

55

gtgccaccac tgaccactg ggtaacatct cagggcct

345

5

<210> 123
 <211> 72
 <212> PRT
 <213> Homo sapiens

10

<400> 123
 Pro Arg Gly Pro Glu Ala Asn Leu Glu Val Arg Pro Lys Glu Ser Trp
 1 5 10 15

15

Asn His Ala Asp Phe Val His Cys Glu Asp Thr Glu Ser Val Pro Gly
 20 25 30

Lys Pro Ser Val Asn Ala Asp Glu Glu Val Gly Gly Pro Gln Ile Cys
 35 40 45

20

Arg Val Cys Gly Asp Lys Ala Thr Gly Tyr His Phe Asn Val Met Thr
 50 55 60

Cys Glu Gly Cys Lys Gly Phe Phe
 65 70

25

<210> 124
 <211> 344
 <212> DNA
 <213> Homo sapiens

30

<220>
 <221> intron
 <222> (1)..(78)

35

<220>
 <221> exon
 <222> (79)..(212)

40

<220>
 <221> intron
 <222> (213)..(344)

45

<220>
 <221> CDS
 <222> (79)..(210)

<400> 124
 aggtggtatg gcccgagacc ccaggccgag ggcccgaggca cccgtgcac ccccttctg 60

50

ctccccattc tctcacag gag ggc cat gaa acg caa cgc ccg gct gag gtg 111
 Glu Gly His Glu Thr Gln Arg Pro Ala Glu Val
 1 5 10

55

EP 1 088 900 A1

5 ccc ctt ccg gaa ggg cgc ctg cga gat cac ccg gaa gac ccg gcg aca 159
 Pro Leu Pro Glu Gly Arg Leu Arg Asp His Pro Glu Asp Pro Ala Thr
 15 20 25

 gtg cca ggc ctg ccg cct gcg caa gtg cct gga gag cgg cat gaa gaa 207
 Val Pro Gly Leu Pro Pro Ala Gln Val Pro Gly Glu Arg His Glu Glu
 30 35 40

10 gga gagtgagcag tgggcgcgcg ggccgggccgg cgccgggggtg cacggctctg 260
 Gly

 agtaaggacg tgccgtgggt gtgtgcatgc ttgtgtggag atgcgcgccg agtgtgcgcg 320

15 tgaacacacg tgcacatgtg agct 344

20 <210> 125
 <211> 44
 <212> PRT
 <213> Homo sapiens

25 <400> 125
 Glu Gly His Glu Thr Gln Arg Pro Ala Glu Val Pro Leu Pro Glu Gly
 1 5 10 15

 Arg Leu Arg Asp His Pro Glu Asp Pro Ala Thr Val Pro Gly Leu Pro
 20 25 30

30 Pro Ala Gln Val Pro Gly Glu Arg His Glu Glu Gly
 35 40

35 <210> 126
 <211> 367
 <212> DNA
 <213> Homo sapiens

40 <220>
 <221> intron
 <222> (1)..(103)

45 <220>
 <221> exon
 <222> (104)..(291)

50 <220>
 <221> intron
 <222> (292)..(367)

55 <220>
 <221> CDS
 <222> (106)..(291)

EP 1 088 900 A1

<400> 126
 ctaacggctt ctgctgcctt gagaggggta cacagtggct ctccaggggg ctggaggctc 60
 5
 accaggggca cgtgtgcctg agccagcctc actgtccctg cagtg atc atg tcc gac 117
 Ile Met Ser Asp
 1
 10 gag gcc gtg gag gag agg cgg gcc ttg atc aag cgg aag aaa agt gaa 165
 Glu Ala Val Glu Glu Arg Arg Ala Leu Ile Lys Arg Lys Lys Ser Glu
 5 10 15 20
 15 cgg aca ggg act cag cca ctg gga gtg cag ggg ctg aca gag gag cag 213
 Arg Thr Gly Thr Gln Pro Leu Gly Val Gln Gly Leu Thr Glu Glu Gln
 25 30 35
 cgg atg atg atc agg gag ctg atg gac gct cag atg aaa acc ttt gac 261
 Arg Met Met Ile Arg Glu Leu Met Asp Ala Gln Met Lys Thr Phe Asp
 40 45 50
 20 act acc ttc tcc cat ttc aag aat ttc cgg gtaggaggaa ctgcacagtg 311
 Thr Thr Phe Ser His Phe Lys Asn Phe Arg
 55 60
 25 acccgaggtg tcaactgccat cttcattctc acatagaaac tgagggtccc caagga 367

 <210> 127
 <211> 62
 <212> PRT
 <213> Homo sapiens
 30
 <400> 127
 Ile Met Ser Asp Glu Ala Val Glu Glu Arg Arg Ala Leu Ile Lys Arg
 1 5 10 15
 35 Lys Lys Ser Glu Arg Thr Gly Thr Gln Pro Leu Gly Val Gln Gly Leu
 20 25 30
 40 Thr Glu Glu Gln Arg Met Met Ile Arg Glu Leu Met Asp Ala Gln Met
 35 40 45
 Lys Thr Phe Asp Thr Thr Phe Ser His Phe Lys Asn Phe Arg
 50 55 60
 45
 <210> 128
 <211> 415
 <212> DNA
 <213> Homo sapiens
 50
 <220>
 <221> intron
 55

<222> (1)..(69)
 <220>
 5 <221> exon
 <222> (70)..(344)
 <220>
 <221> intron
 10 <222> (345)..(415)
 <220>
 <221> CDS
 <222> (70)..(342)
 15 <400> 128
 ctgagttggg acctgtctat gaaagcacat gctgtctctc ctctgtccac ctcttggeat 60
 gtgtcctag ctg cca ggg gtg ctt agc agt ggc tgc gag ttg cca gag tct 111
 20 Leu Pro Gly Val Leu Ser Ser Gly Cys Glu Leu Pro Glu Ser
 1 5 10
 ctg cag gcc cca tgc agg gaa gaa gct gcc aag tgg agc cag gtc cgg 159
 Leu Gln Ala Pro Ser Arg Glu Glu Ala Ala Lys Trp Ser Gln Val Arg
 15 20 25 30
 25 aaa gat ctg tgc tct ttg aag gtc tct ctg cag ctg cgg ggg gag gat 207
 Lys Asp Leu Cys Ser Leu Lys Val Ser Leu Gln Leu Arg Gly Glu Asp
 35 40 45
 30 ggc agt gtc tgg aac tac aaa ccc cca gcc gac agt ggy ggg aaa gag 255
 Gly Ser Val Trp Asn Tyr Lys Pro Pro Ala Asp Ser Xaa Gly Lys Glu
 50 55 60
 atc ttc tcc ctg ctg ccc cac atg gct gac atg tca acc tac atg ttc 303
 35 Ile Phe Ser Leu Leu Pro His Met Ala Asp Met Ser Thr Tyr Met Phe
 65 70 75
 aaa ggc atc atc agc ttt gcc aaa gtc atc tcc tac ttc aggtaggaca 352
 Lys Gly Ile Ile Ser Phe Ala Lys Val Ile Ser Tyr Phe
 40 80 85 90
 45 tggagactgg gtggttgggt gtggaaaaga actggaagt gccaggaggt tcaaagggcc 412
 tgg 415
 <210> 129
 <211> 91
 <212> PRT
 <213> Homo sapiens
 50 <400> 129
 Leu Pro Gly Val Leu Ser Ser Gly Cys Glu Leu Pro Glu Ser Leu Gln
 1 5 10 15
 55

EP 1 088 900 A1

Ala Pro Ser Arg Glu Glu Ala Ala Lys Trp Ser Gln Val Arg Lys Asp
20 25 30

5 Leu Cys Ser Leu Lys Val Ser Leu Gln Leu Arg Gly Glu Asp Gly Ser
35 40 45

Val Trp Asn Tyr Lys Pro Pro Ala Asp Ser Xaa Gly Lys Glu Ile Phe
10 50 55 60

Ser Leu Leu Pro His Met Ala Asp Met Ser Thr Tyr Met Phe Lys Gly
65 70 75 80

15 Ile Ile Ser Phe Ala Lys Val Ile Ser Tyr Phe
85 90

20 <210> 130
<211> 598
<212> DNA
<213> Homo sapiens

25 <220>
<221> intron
<222> (1)..(66)

30 <220>
<221> exon
<222> (67)..(209)

<220>
<221> intron
<222> (210)..(410)

35 <220>
<221> exon
<222> (411)..(527)

40 <220>
<221> intron
<222> (528)..(598)

45 <220>
<221> CDS
<222> (68)..(209)

<220>
<221> CDS
<222> (411)..(526)

50 <400> 130
ctgctggtgc cggcctgtgg gctgcctccc agggagctgt cctcccctcc ccataccttgc 60

55

5

10

15

20

25

30

35

40

45

50

55

64

EP 1 088 900 A1

Leu Lys Lys Leu Gln Leu His Glu Glu Glu Tyr Val Leu Met Gln Ala
65 70 75 80

5 Ile Ser Leu Phe Ser Pro
85

10 <210> 132
<211> 271
<212> DNA
<213> Homo sapiens

15 <220>
<221> intron
<222> (1)..(77)

20 <220>
<221> exon
<222> (78)..(183)

25 <220>
<221> intron
<222> (184)..(271)

30 <400> 132
gagcaatgcc ctgactctgg gctggactga gcttgtcttt gccccatgat cttgcaccac 60
acctccctcc cctccagac cgc cca ggt gtg ctg cag cac cgc gtg gtg gac 112
Arg Pro Gly Val Leu Gln His Arg Val Val Asp
1 5 10

35 cag ctg cag gag caa ttc gcc att act ctg aag tcc tac att gaa tgc 160
Gln Leu Gln Glu Gln Phe Ala Ile Thr Leu Lys Ser Tyr Ile Glu Cys
15 20 25

40 aat cgg ccc cag cct gct cat aggtgagcac agcagggggt gaggaccgt 211
Asn Arg Pro Gln Pro Ala His
30

45 gaggggtgatg tgagggagcc gaggttcagg gaaattgccc aagacttcat ggccagaggg 271

50 <210> 133
<211> 34
<212> PRT
<213> Homo sapiens

<400> 133
Arg Pro Gly Val Leu Gln His Arg Val Val Asp Gln Leu Gln Glu Gln

55

EP 1 088 900 A1

```

1           5           10           15
Phe Ala Ile Thr Leu Lys Ser Tyr Ile Glu Cys Asn Arg Pro Gln Pro
5          20          25          30

Ala His

10

<210> 134
<211> 324
<212> DNA
<213> Homo sapiens
15

<220>
<221> intron
<222> (1)..(83)

20

<220>
<221> exon
<222> (84)..(224)

25

<220>
<221> 3'UTR
<222> (226)..(324)

30

<220>
<221> CDS
<222> (85)..(225)

<400> 134
tgcttgtagc gcctcagagc agcctgagg cttgtgggtc agggcgggct gcacccacaa 60

35  tcttttctct ggctggcatg cagg ttc ttg ttc ctg aag atc atg gct atg      111
           Phe Leu Phe Leu Lys Ile Met Ala Met
           1           5

ctc acc gag ctc cgc agc atc aat gct cag cac acc cag cgg ctg ctg      159
Leu Thr Glu Leu Arg Ser Ile Asn Ala Gln His Thr Gln Arg Leu Leu
40  10           15           20           25

cgc atc cag gac ata cac ccc ttt gct acg ccc ctc atg cag gag ttg      207
Arg Ile Gln Asp Ile His Pro Phe Ala Thr Pro Leu Met Gln Glu Leu
           30           35           40

45  ttc ggc atc aca ggt agc tgagcggctg cccttgggtg acacctccga      255
Phe Gly Ile Thr Gly Ser
           45

50  gaggcagcca gacccagagc cctctgagcc gccactcccg ggccaagaca gatggacact 315
gccaagagc      324

55

```

<210> 135
 <211> 47
 <212> PRT
 <213> Homo sapiens

<400> 135
 Phe Leu Phe Leu Lys Ile Met Ala Met Leu Thr Glu Leu Arg Ser Ile
 1 5 10 15
 Asn Ala Gln His Thr Gln Arg Leu Leu Arg Ile Gln Asp Ile His Pro
 20 25 30
 Phe Ala Thr Pro Leu Met Gln Glu Leu Phe Gly Ile Thr Gly Ser
 35 40 45

Claims

1. A polynucleotide selected from the group consisting of:

- (a) polynucleotides comprising a nucleotide sequence encoding the amino acid sequence encodable by a nucleotide sequence of SEQ ID NO: 86, 94 and/or 98;
- (b) polynucleotides comprising a nucleotide sequence encoding a molecular variant of the cytochrome CYP3A4 protein by way of at least one amino acid deletion, addition and/or substitution at an amino acid position corresponding amino acid residue Gly56 in exon 3 of the CYP3A4 gene;
- (c) polynucleotides comprising a nucleotide sequence encoding a molecular variant of the cytochrome CYP3A7 protein by way of at least one amino acid deletion, addition and/or substitution, preferably at an amino acid position corresponding amino acid residue Thr 409 in exon 11 of the CYP3A7 gene;
- (d) polynucleotides comprising a nucleotide sequence of any one of SEQ ID NOS: 86, 87, 90, 91, 94, 95 or 108;
- (e) polynucleotides comprising a nucleotide sequence of any one of SEQ ID NOS: 98, 99, 102, 103, 106 or 107; and
- (f) polynucleotides comprising a nucleotide sequence encoding a CYP3A4 or CYP3A7 polypeptide or fragment thereof having an epitope comprising an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 86 and/or 94.

2. The polynucleotide of claim 1, wherein said polynucleotide encodes a variant CYP3A4, CYP3A7 or hPXR protein or fragment thereof.

3. The polynucleotide of claim 1 or 2, wherein said amino acid substitution comprises Gly56 to Asp in exon 3 of the CYP3A4 gene and/or Thr409 to Arg in exon 11 of the CYP3A7 gene.

4. The polynucleotide of any one of claims 1 to 3, wherein the nucleotide deletion, addition and/or substitution result in altered expression of the variant CYP3A4, CYP3A7 or hPXR gene compared to the corresponding wild type gene.

5. A vector comprising the polynucleotide of any one of claims 1 to 4.

6. The vector of claim 5, wherein the polynucleotide is operatively linked to expression control sequences allowing expression in prokaryotic or eukaryotic cells.

7. A host cell genetically engineered with the polynucleotide of any one of claims 1 to 4 or the vector of claim 5 or 6.

8. A method for producing a molecular variant CYP3A4, CYP3A7 or hPXR protein or fragment thereof comprising

- (a) culturing the host cell of claim 7; and

(b) recovering said protein or fragment from the culture.

9. A method for producing cells capable of expressing a molecular variant CYP3A4, CYP3A7 or hPXR gene comprising genetically engineering cells with the polynucleotide of any one of claims 1 to 4 or the vector of claim 5 or 6.

10. A CYP3A4, CYP3A7 or hPXR protein or fragment thereof encoded by the polynucleotide of any one of claims 1 to 4 or obtainable by the method of claim 8 or from cells produced by the method of claim 9.

11. An antibody which binds specifically to the protein of claim 10.

12. The antibody of claim 11 which specifically recognizes an epitope containing one or more amino acid substitution (s) as defined in any one of claims 1 to 4.

13. A nucleic acid molecule complementary to a polynucleotide of any one of claims 1 to 4.

14. A nucleic acid molecule capable of specifically recognizing and cleaving the polynucleotide of any one of claims 1 to 4.

15. A vector comprising the nucleic acid molecule of claim 13 or 14.

16. A transgenic non-human animal comprising at least one polynucleotide of any one of claims 1 to 4 or the vector of claim 5 or 6.

17. The transgenic non-human animal of claim 16 further comprising at least one inactivated wild type allele of the CYP3A4, CYP3A7 or hPXR gene.

18. The transgenic non-human animal of claim 16 or 17, which is a mouse or a rat.

19. A method of identifying and obtaining a CYP3A4, CYP3A7 or hPXR inhibitor capable of modulating the activity of a molecular variant of the CYP3A4, CYP3A7 or hPXR gene or its gene product comprising the steps of

(a) contacting the protein of claim 10 or a cell expressing a molecular variant CYP3A4, CYP3A7 or hPXR gene comprising a polynucleotide of any one of claims 1 to 4 in the presence of components capable of providing a detectable signal in response to drug metabolism, with a compound to be screened under conditions to permit CYP3A4- or CYP3A7-mediated drug metabolism, and

(b) detecting the presence or absence of a signal or increase of a signal generated from the drug metabolism, wherein the presence or increase of the signal is indicative for a putative inhibitor.

20. The method of claim 19 wherein said cell is a cell of claim 7, obtained by the method of claim 9 or is comprised in the transgenic non-human animal of any one of claims 16 to 18.

21. A method of identifying and obtaining an CYP3A4, CYP3A7 or hPXR inhibitor capable of modulating the activity of a molecular variant of the CYP3A4, CYP3A7 or hPXR gene or its gene product comprising the steps of

(a) contacting the protein of claim 10 with a first molecule known to be bound by CYP3A4, CYP3A7 or hPXR protein to form a first complex of said protein and said first molecule;

(b) contacting said first complex with a compound to be screened; and

(c) measuring whether said compound displaces said first molecule from said first complex.

22. The method of claim 21, wherein said measuring step comprises measuring the formation of a second complex of said protein and said compound.

23. The method of claim 21 or 22, wherein said measuring step comprises measuring the amount of said first molecule that is not bound to said protein.

24. The method of any one of claim 21 to 23 wherein said first molecule is nifedipine, rifampicine or corticosterone.

25. The method of any one of claims 21 to 24 wherein said first molecule is labeled.

26. A method of diagnosing a disorder related to the presence of a molecular variant of the CYP3A4, CYP3A7 or hPXR gene or susceptibility to such a disorder comprising

- (a) determining the presence of a polynucleotide of any one of claim 1 to 4 in a sample from a subject; and/or
- (b) determining the presence of a protein of claim 10.

27. The method of claim 26, wherein said disorder is cancer.

28. The method of claim 26 or 27 comprising PCR, ligase chain reaction, restriction digestion, direct sequencing, nucleic acid amplification techniques, hybridization techniques or immunoassays.

29. The method of any one of claims 26 to 28, further comprising administering to a subject a medicament to abolish or alleviate said disorder.

30. The method of any one of claims 26 to 29, further comprising introducing

- (i) a functional and expressible wild type CYP3A4, CYP3A7 or hPXR gene or
- (ii) a nucleotide acid molecule of claim 13 or 14 or the vector of claim 15 into cells.

31. A method for the production of a pharmaceutical composition comprising the steps of the method of any one of claims 19 to 25; and

- (c) synthesizing and/or formulating the compound identified and obtained in step (b) or a derivative thereof in a pharmaceutically acceptable form.

32. A method for the preparation of a pharmaceutical composition comprising formulating a drug or pro-drug in the form suitable for therapeutic application and preventing or ameliorating the disorder of the subject diagnosed in the method of claim 26 or 27.

33. The method of claim 31 or 32 wherein said compound drug or prodrug is a derivative of a medicament as defined in claim 29.

34. An inhibitor identified or obtainable by the method of any one of claims 19 to 25.

35. The inhibitor of claim 34 which binds specifically to the protein of claim 10.

36. Use of an oligo- or polynucleotide for the detection of a polynucleotide of any one of claims 1 to 4 and/or for genotyping of individual CYP3A4, CYP3A7 or hPXR alleles.

37. The use of claim 36 wherein said polynucleotide is a polynucleotide of any one of claims 1 to 4 or a nucleic acid molecule of claim 13 or 14.

38. The use of claim 36 wherein said oligonucleotide is about 15 to 50 nucleotides in length and comprises the nucleotide sequence of any one of SEQ ID NOS: 1 to 107 or a complementary sequence.

39. A primer or probe consisting of an oligonucleotide as defined in claim 38.

40. Use of an antibody or a substance capable of binding specifically to the gene product of an CYP3A4, CYP3A7 or hPXR gene for the detection of the protein of claim 10, the expression of a molecular variant CYP3A4, CYP3A7 or hPXR gene comprising a polynucleotide of any one of claims 1 to 4 and/or for distinguishing CYP3A4 or hPXR alleles comprising a polynucleotide of any one of claims 1 to 4.

41. A composition comprising the polynucleotide of any one of claims 1 to 4, the vector of claim 5 or 6, the host cell of claim 7 or obtained by the method of claim 9, the protein of claim 10, the antibody of claim 11 or 12, the nucleic acid molecule of claim 13 or 14, the vector of claim 15, the inhibitor of claim 34 or the primer or probe of claim 39.

42. The composition of claim 41 which is a diagnostic or a pharmaceutical composition.

43. Use of an effective dose of a drug or prodrug for the preparation of a pharmaceutical composition for the treatment

or prevention of a disorder of a subject comprising a polynucleotide of any one of claims 1 to 4 in its genome.

44. The use of 43 wherein said disorder is cancer.

5

10

15

20

25

30

35

40

45

50

55




Fig. 1




Fig. 2





Fig. 3




4
Lib

CYP3A4 polymorphisms

Exon 3 (G235A; Gly56Asp)



Intron 7 (T→G)



A CYP3A7 exon 11 polymorphism (C1229G; Thr409Arg)





Fig. 5

hPXR polymorphisms


Exon 1b (C149A, untranslated)

wt/mut




Exon 5/6 (CC975TT, silent)

wt/wt



mut/mut



Intron 7 (C→T)

wt/mut




Fig. 6




Fig. 7

Fig. 8

CYP3A4

Exon 3 (G235A Gly56Asp)

CCTCTAACTGCCAGCAAGTCIGATTTCATTGGCTTCGACTGTTTTCATCCCAATTAGAGG
 CAGGGTTAAGTACATTAAAAATAATAATCAAATATTATTTGTTTCTCCTCCCAGGG→AC
 TTTTGTATGTTTGACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGGIGAGTATT
 CTGGAACTTCCATTGGATAGACTTGTTTCTATGATGAGTTTACCCCACTGCACAGAGGA
CAGTCTCAGCCC

Exon 4

AGTCTGGCTTCCTGGGTTGGGCTCCAGCTGTAGAATAAGGCTGTTGATGTTTAATCAAC
 TCTGTTTTTTTACACAGCTTTTATGATGGTCAACAGCCTGTGCTGGCTATCACAGATC
 CTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCTGTCTTCACAAACCGGAG
 GGTAAAGCATTGATGTTGAAATTAATACTGATTGATTAAATTTATATTTGAAATTCTT
 ATATATTCATAGACAGTTGCCTAAAAAATGTCCAGGAAGGTTCCACGTCCACTTC

Exon 5

CTACAACCATGGAGACCTCCACAACTGATGTAGGACAAAATGTTTCTGCTTTGAACTCT
AGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATAGCTGAGGATGAAGA
 ATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGAAAACCAAGGA
 GGTATGAAAATAACATGAGTTTTAATAAGAACTTAAAGAATGAATCTGGTGGGGACAG
GTA

Exon 7 (T/G intron 7 polymorphism)

GTCTGTCTTGACTGGACATGTGGCTTTCCTGATGCACGCATAGAGGAAGGATGGTAAA
 AAGGTGCTGATTTTAATTTCCACATCTTCTCCACTCAGCGTCTTTGGGGCCTACAGC
 ATGGATGTGATCACTAGCACATCATTGGAGTGAACATCGACTCTCTCAACAATCCAC
 AAGACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATT
 TTTCTCTCAATAAGTATGTGGACTACTATTTCTTTTATTTATCTT→GCTCTCTTAAAAA
 TAACTGCTTTATTGAGATATAAATCACCATGTAATTCATCCACTTAAATATACAGTTCAG
 TGATTTGTAGTACATTTGAAGATATGTGTGACCATCATC

Fig. 8 (continued)

Exon 9

GGAGATCAAGGACCACGCTTGTGATTACTTCTGACTTCAGGAGCCACTTTCTGTCAGT
GAAATTTCTCTTTTTGCTTCTAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTC
AGAATTCAAAAGAACTGAGTCCCACAAAGGTAACCAGAGTGTTTCTGAGGGCTACTT
GTGGGGCACTCAGAGGGAAGGCCTTGTTCTGAAAATGTGCAGGAAGTATTCCAGGATG
ATGAG

CYP3A7

Exon 11 (C1229G Thr409Arg polymorphism)

CCAGTATGAGTTGTTCTCTGGAACTTCTAACAGTTCAACAGTACTACATGGACTGAGTTA
 AAAGTTAATTCAAAAATCTCAATTTATCCAAATCTGTTTCTTTCTTTTCAGGCACCACCCA
 CCTATGATACTGTGCTACAGTTGGAGTATCTTGACATGGTGGTGAATGAAACACTCAG
 ATTATTCCCAGTTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGATGTTGAAATCAAT
 GGGATGTTTATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGTTCTTCATCATG
 ACCCAAAGTACTGGAC→GAGAGCCTGAGAAGTTCCTCCCTGAAAGGTAGGAGGCCC
 CTGGGAAGGGAGCCCTCCCTGAACCAGCCTGGTTCAAGCATATTCTGCCT

hPXR

Exon 1b&1a (in bold in exon 1b: nn 1-280 of hPXR cDNA (GenBank AF061056.1),
 dotted: nn 36-257 of PAR1 cDNA (GenBank AF084645))

TCAAGTGCTGGACTTGGGACTTAGGAGGGGCAATGGAGCCGCTTAGTGCCTACATCTG
 ACTTGGACTGAAATATAGGTGAGAGACAAGATTGTCTCATATCCGGGGAAATCATAAC
 CTATGACTAGGACGGGAAGAGGAAGCACTGCCTTTACTTCAGTGGGAATCTCGGCCT
CAGCCTGCAAGCCAAGTGTTACAGTGAAAAAGCAAGAGAATAAGCTAATACTCCT
GTCCTGAAC→AAAGGCAGCGGCTCCTTGGTAAAGCTACTCCTTGATCGATCCTTTGCA
CCGGATTGTTCAAAGTGGACCCAGGGGAGAAGTCGGAGCAAAGAACTTACCACCAA
GCAGGTATGGTTTTTCTTTCTTTCTTTTGCTGGGGGCTGACCGCCCTTCAGCTCCAG
 CCAAAGATGTGTGTGAACACAAATATACCTTCTGTT

Fig. 8 (continued)

TGAGGTCAGCATCATAGTGGGTCGTGAATCATGTTGGCCTTGCTGCTGTCTCCTCATTT
 CTAGGGTGAAAAAAAAAAGCATGAAAACAATCACTTAATGTTGAGCCCCATTA
 CTGATGCTCTCTGGTCCTGCACTAGCCTCCTAGAAAAATCACCACAGCCTTAACTACTG
 CATGAGTTACCACAAGTCACACATAACAACAGCTCCCTGTTACAGGGCTGGAGTCCCTG
 GACCCAGGAAATACCACCTCCAAGGACTGTGGGAGCTGGGGACTATGGGAACTGGGAT
 CAACTCAGTCCTGATTCTTTTGGCCTGCTGGGTTAGTGCTGGCAGCCCCCTGAGGC
 CAAGGACAGCAGCATGACAGTCACCAGGACTCACCCTTCAAGGAGGGGTCCCTCAG
 AGCACCTGCCATACCCCTGCACAGTGCTGCGGCTGAGTTGGCTTCAAACCAAGTGAAGTT
 TTCTACCTCTACTATTGAAAGGGCACCTGTCCACAGAACCAGTCTTGCCTGCATGT
 GG

EXON 2

CTGAGGCCTCTACACATCCCTGTCCAGTCTTTTCATTCTCTGTGGTTTTCTCATTTCTAGT
 CCAAGAGGCCCAGAAGCAAACCTGGAGGTGAGACCCAAAGAAAGCTGGAACCATGC
 TGACTTTGTACACTGTGAGGACACAGAGTCTGTTCCCTGGAAAGCCCAGTGTC AACGCA
 GATGAGGAAGTCGGAGGTCCCCAAATCTGCCGTGTATGTGGGGACAAGGCCACTGGC
 TATCACTTCAATGTCATGACATGTGAAGGATGCAAGGGCTTTTTTCAGGTAGAGTTACCC
 ATCAGCCTTCACCCACGTGCCACCACTGACCCACTGGGTAACATCTCAGGGCCT

Exon 3

AAGTGGTATGGCCCGGAGCCCCAGGCCGAGGGCCCGGGCACCCGTGCATCCCCCCTT
 CTGCTCCCCATTCTCTCACAGGAGGGCCATGAAACGCAACGCCCGGCTGAGGTGCCC
 CTTCCGGAAGGGCGCCTGCGAGATCACCCGGAAGACCCGGCGACAGTGCCAGGCCT
 GCCGCCTGCGCAAGTGCCTGGAGAGCGGCATGAAGAAGGAGAGTGAGCAGTGGGCG
 CGCGGGCGGGCCGGCGCCGGGGTGACGGCTCTGAGTAAGGACGTGCCGTGGGTGT
 GTGCATGCTTGTGTGGAGATGCGCGCCGAGTGTGCGCGTGAACACACGTGCACATGTG
 AGCT

EXON 4

CTAACGGCTTCTGCTGCCCTTGAGAGGGTTACACAGTGGCTCTCCAGGGGGCTGGAGGC
 TCACCAGGGGCACGTGTGCCTGAGCCAGCCTCACTGTCCCTGCAGTGATCAT

Fig. 8 (continued)

GTCCGACGAGGCCGTGGAGGAGAGGCGGGCCTTGATCAAGCGGAAGAAAAGTGAAC
 GGACAGGGACTCAGCCACTGGGAGTGCAGGGGCTGACAGAGGAGCAGCGGATGATG
 ATCAGGGAGCTGATGGACGCTCAGATGAAAACCTTTGACACTACCTTCTCCATTTC
 AGAATTTCCGGGTAGGAGGAACTGCACAGTGACCCGAGGTGTCACTGCCATCTTCATT
 CTCACATAGAACTGAGGTTCCCCAAGGA

Exon5/6

CTGAGTTGGGACCTGTCTATGAAAGCACATGCTGTCTCTCCTCTGTCCACCTCCTGGCA
 TGTGTCTCTAGCTGCCAGGGGTGCTTAGCAGTGGCTGCGAGTTGCCAGAGTCTCTGCA
 GGCCCCATCGAGGGAAGAAGCTGCCAAGTGGAGCCAGGTCCGGAAAGATCTGTGCT
 CTTTGAAGGTCTCTCTGCAGCTGCGGGGGGAGGATGGCAGTGTCTGGAACACAAAC
 CCCCAGCCGACAGTGGC→TGGGAAAGAGATCTTCTCCCTGCTGCCCCACATGGCTGA
 CATGTCAACCTACATGTTCAAAGGCATCATCAGCTTTGCCAAAGTCATCTCCTACTTCA
 GGTAGGACATGGAGACTGGGTGGTTGGGTGTGGAAAAGAACTGGAAGTGGCCAGGAG
GTTCAAAGGGCCTGG

EXONS 7&8

CTGCTGGTGCCGGCCTGTGGGCTGCCTCCCAGGGAGCTGTCCTCCCCTCCCCATCCTT
 GCTGCCAGGGACTTGCCCATCGAGGACCAGATCTCCCTGCTGAAGGGGGCCGCTTTC
 GAGCTGTGTCAACTGAGATTCAACACAGTGTTCAACGCGGAGACTGGAACCTGGGAG
 TGTGGCCGGCTGTCTACTGCTTGGAAAGACACTGCAGGTGCCCCGAGAGAGCCTGCCT
 GCCCTGGCAGAGGGAGGGAAACACTGCAGTTATGGGAGGAAGGGAGCTACGCCAGGA
 TATGCAGGTTCTGGGATGGCAGGGCAGGAAGATGGAATGGTGGAAAACAAGATATTGG
 TGAGGGATGATTAGATCTTGGTCAGCTTGCTGAGAAGCTGCCCCTCCATC→TCTGTTAC
 CATCCACAGGTGGCTTCCAGCAACTTCTACTGGAGCCCATGCTGAAATTCCACTACAT
 GCTGAAGAAGCTGCAGCTGCATGAGGAGGAGTATGTGCTGATGCAGGCCATCTCCCT
 CTTCTCCCCAGGTGAGGATCTCCCCTAGGCTGCCTGACATCCCCCCCAGCCTTATCTG
CCCTCCCAGGGAAGGTCCCAGTC

EXON 9

GAGCAATGCCCTGACTCTGGGCTGGACTGAGCTTGTCTTTGCCCCATGATCTTGCACCA
 CACCTCCCTCCCCTCCAGACCGCCCAGGTGTGCTGCAGCACCGCGTGGTGG

Fig. 8 (continued)

ACCAGCTGCAGGAGCAATTCGCCATTACTCTGAAGTCCTACATTGAATGCAATCGGCC
CCAGCCTGCTCATAGGIGAGCACAGCAGGGGGTGAGGACCCGTGAGGGTGATGTGAG
GGAGCCGAGGTTGAGGGAAATTGCCCAAGACTTCATGGCCAGAGGG

EXON 9A

TGCTTGTCAGCCTCAGAGCAGCCCTGAGGCTTGTGGGTCAGGGCGGGCTGCACCCA
CAATCTTTTCTCTGGCTGGCATGCAGGTTCTTGTTCCTGAAGATCATGGCTATGCTCAC
CGAGCTCCGCAGCATCAATGCTCAGCACACCCAGCGGCTGCTGCGCATCCAGGACAT
ACACCCCTTTGCTACGCCCCTCATGCAGGAGTTGTTTCGGCATCACAGGTAGCTGAGC
GGCTGCCCTTGGGTGACACCTCCGAGAGGCAGCCAGACCCAGAGCCCTCTGAGCCG
CCTCTCCCGGGCCAAGACAGATGGACACTGCCAAGAGC



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 99 11 8120 shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 99 13106 A (AXYS PHARM INC) 18 March 1999 (1999-03-18) * the whole document *	1,13,14, 19-28, 36-39, 41-44	C12Q1/68 C12P19/34 C12N9/02 C07K16/18 C12N15/53 A61K38/17 A61P35/00 A01K67/027
X	WESTLIND A ET AL.,: " Interindividual differences in hepatic expression of CYP3A4: Relationship to genetic polymorphism in the 5'-upstream regulatory region." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 259, 27 May 1999 (1999-05-27), page 201-205 XP000907112 * the whole document *	1-4,13, 14,19, 21,26-33	
D,X	HASHIMOTO H. ET AL.,: "Gene structure of CYP3A4 an adult-specific form of cytochrome P450 in human livers and its transcriptional control" EUR. J. BIOCHEM., vol. 218, 1993, page 585-595 XP000910643 * the whole document *	1-4,13, 36-39	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C12Q
INCOMPLETE SEARCH <p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely</p> <p>Claims searched incompletely:</p> <p>Claims not searched:</p> <p>Reason for the limitation of the search: see sheet C</p>			
Place of search BERLIN		Date of completion of the search 3 August 2000	Examiner Mateo Rosell, A.M.
CATEGORY OF CITED DOCUMENTS <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03 82 (P44027)



European Patent
Office

**INCOMPLETE SEARCH
SHEET C**

Application Number
EP 99 11 8120

Although claim 29 is directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.

Claim(s) searched incompletely:
34,35

Reason for the limitation of the search:

Claims 34 and 35 refer to an inhibitor identified or obtainable by screening compounds able to displace the protein of claim 10 when is bound to the ligand from claim 24. No such compounds are defined in the application. In consequence the scope of said claim is ambiguous and vague, and its subject-matter is not sufficiently disclosed and supported (Art. 83 and 84 EPC).

Therefore, no search can be carried out for such speculative claims whose wording is, in fact, a mere recitation of the result to be achieved.

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 99 11 8120

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
D,X	BEAUNE P.H. ET AL.,: "Isolation and sequence determination of a cDNA clone related to human cytochrom P-450 nifedipine oxidase" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, USA, vol. 83, 1986, pages 8064-8068, XP000907192 * the whole document *	1-4,13, 36-39	
X	DOTZLAW H ET AL., : "The human organ receptor PXR messenger RNA is expressed in both normal and neoplastic breast tissue." CLINICAL CANCER RESEARCH, vol. 5, August 1999 (1999-08), pages 2103-2107, XP000929536 * the whole document *	1,2,6-8, 13-15, 26-28	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
D,X	LEHMANN J M ET AL.,: "The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions." JOURNAL OF CLINICAL INVESTIGATION, vol. 102, 1 September 1998 (1998-09-01), page 1016-1023 XP000909297 * the whole document *	1-4,13, 36-39	
D,X	BERTILSSON G. ET AL.,: "Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction" PROC. NATL. ACAD. SCI. U.S.A., vol. 95(21), 1998, page 12208-12213 XP002921167 * the whole document *	1-4,13, 36-39	



European Patent
Office

Application Number

EP 99 11 8120

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- ☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet 8

- ☒ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
- ☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- ☐ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:



European Patent
Office

**LACK OF UNITY OF INVENTION
SHEET B**

Application Number

EP 99 11 8120

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims: 1,3 completely and 2,4-44 all partially

Polynucleotides comprising a nucleotide sequence encoding a molecular variant of the cytochrome CYP3A4 or CYP3A7 protein and vectors, host cells, antibodies, nucleic acid molecules, transgenic non-human animals, pharmaceutical compositions, probes or oligonucleotides thereof as well as methods of diagnostic or identification of inhibitors capable of modulating the activity of a molecular variant of CYP3A4 or CYP37A.

2. Claims: 2,4-44 all partially

Polynucleotides comprising a nucleotide sequence encoding a molecular variant of the cytochrome hPXR protein and vectors, host cells, antibodies, nucleic acid molecules, transgenic non-human animals, pharmaceutical compositions, probes or oligonucleotides thereof as well as methods of diagnostic or identification of inhibitors capable of modulating the activity of a molecular variant of hPXR.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 99 11 8120

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	WO 96 33287 A (INST NAT SANTE RECH MED ;GARCHON HENRI JEAN (FR); BACH JEAN FRANCO) 24 October 1996 (1996-10-24) * page 7 *	1	
X	WO 98 20165 A (WHITEHEAD BIOMEDICAL INST ;HUDSON THOMAS (US); LANDER ERIC S (US);) 14 May 1998 (1998-05-14) see pages 70, 83, 95, 219, 227 for sequence identification.	1	
A	WO 91 10745 A (IMP CANCER RES TECH) 25 July 1991 (1991-07-25) * the whole document *	1-4,13, 14,19, 21, 26-33, 36-39	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
A	EP 0 759 476 A (OTSUKA PHARMA CO LTD) 26 February 1997 (1997-02-26) * the whole document *	1-4,13, 14,19, 21, 26-33, 36-39	
D,A	PASCUSSI J-M ET AL.,: "Evidence for the presence of a functional Pregnane X Receptor response element in the CYP3A7 promoter gene." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 260, 5 July 1999 (1999-07-05), page 377-381 XP000907111 * the whole document *	1-4,13, 14,19, 21,24	
	---	-/--	



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 99 11 8120

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	ZHANG HE ET AL: "Rat pregnane X receptor: Molecular cloning, tissue distribution, and xenobiotic regulation." ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 368, no. 1, 1 August 1999 (1999-08-01), pages 14-22, XP000933837 ISSN: 0003-9861 * the whole document *	1,2,6-8, 13-15, 26-28	
E	WO 99 48915 A (GLAXO GROUP LTD ;KIEWER STEVEN ANTHONY (US); WILLSON TIMOTHY MARK) 30 September 1999 (1999-09-30) * the whole document *	1-10, 13-23, 28-39, 42,43	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
T	JONES STACEY A ET AL: "The pregnane X receptor: A promiscuous xenobiotic receptor that has diverged during evolution." MOLECULAR ENDOCRINOLOGY, vol. 14, no. 1, January 2000 (2000-01), pages 27-39, XP000933600 ISSN: 0888-8809 * the whole document *	1,2,6-8, 13-15, 26-28	
T	SATA F ET AL.: "CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity" CLINICAL PHARMACOLOGY & THERAPEUTICS, vol. 67, January 2000 (2000-01), page 48-56 XP000910497 * the whole document *	1,13,14, 19, 26-33, 36-39	

EPO FORM 1533 (3.82) (page 1/3)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 11 8120

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

03-08-2000

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9913106	A	18-03-1999	AU 9128798 A	29-03-1999
			EP 1012340 A	28-06-2000
WO 9633287	A	24-10-1996	FR 2733251 A	25-10-1996
WO 9820165	A	14-05-1998	EP 0941366 A	15-09-1999
WO 9110745	A	25-07-1991	AT 140488 T	15-08-1996
			AU 642705 B	28-10-1993
			AU 7179191 A	05-08-1991
			CA 2071636 A	19-07-1991
			DE 69120936 D	22-08-1996
			DE 69120936 T	20-02-1997
			EP 0511262 A	04-11-1992
			GB 2256271 A, B	02-12-1992
			JP 5503845 T	24-06-1993
			US 5981174 A	09-11-1999
EP 0759476	A	26-02-1997	JP 7298900 A	14-11-1995
			CA 2189638 A	16-11-1995
			CN 1151763 A	11-06-1997
			WO 9530772 A	16-11-1995
WO 9948915	A	30-09-1999	AU 3211699 A	18-10-1999

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82